

BORNATER

CHILDREN'S TUMOR FOUNDATION



Contents

- **3** Letter from the President
- 4 Leading the Way: CTF Strategic Plan
- 6 The Path to FDA Approval: Selumetinib
- 8 Attracting Pharma
- **10** Driving Collaboration
- 12 Fueling Discovery
- 14 Accelerating Innovation
- 16 NF Conference & Hackathon
- 17 CTF Europe
- 18 Sustaining Hope
- 20 Spreading Awareness
- 22 Raising Funds
- 24 Advocacy
- 25 National Ambassador
- 26 Financial Summary
- 28 Donors

What is NF?

NF is a term for a group of genetic conditions that cause tumors to grow on nerves throughout the body. NF includes neurofibromatosis type 1 (NF1) and all types of schwannomatosis (SWN), including *NF2*-related schwannomatosis (NF2), formerly known as neurofibromatosis type 2. Some type of neurofibromatosis or schwannomatosis occurs in approximately one in every 2,000 births. These conditions affect all populations equally, and may lead to blindness, deafness, bone abnormalities, disfigurement, learning challenges, disabling pain, or cancer.



KNOW A FIGHTER

The Children's Tumor Foundation

is the world's leading nonprofit dedicated to funding and driving innovative research that will result in effective treatments for the millions of people worldwide who live with NF.

Our mission

Drive research, expand knowledge, and advance care for the NF community.

Our vision



CHILDREN'S VAL TUMOR FOUNDATION ENDING NE THROUGH RESEARCH

Q

Dear friends,

As I reflect on the last year, I am thrilled by our progress in advancing treatments for NF patients. At the Children's Tumor Foundation (CTF), 2022 was defined by a thoughtful, forward-looking view as we built a bold, visionary five-year strategic plan dedicated to expediting effective and tolerable treatments to patients. I could not be prouder of this transformational vision, which is summarized in this annual report. As we move forward, our unwavering focus is to lead and accelerate the innovation that ends NF. We focus on investing in high-impact projects that will accelerate treatments, strengthen clinical trials, and empower stakeholders. We will not quit until there are treatments for all manifestations of all types of NF.

Recognizing the inherent strength in collaboration, we realize this ambitious mission cannot be achieved alone, and CTF remains committed to forging fruitful partnerships and growing our community. We continue to invite pharmaceutical and biotech companies to negotiate access to additional drugs for clinical trials.

The year has landed us in an exciting moment, with many treatment options on the horizon!

Ten pharmaceutical companies are now working on NF, of which two are entirely dedicated to NF. NFlection Therapeutics is running a Phase 2b clinical trial with a topical MEK inhibitor; SpringWorks Therapeutics is showing encouraging data with a MEK inhibitor drug; and the INTUITT-NF2 clinical platform trial has shown encouraging data on Brigatinib, and has now included a second drug, Neratinib. Lastly, in collaboration with other funders, our investments in gene therapy are showing real promise.

Our NF Conference continues its reign as the most important meeting for NF in the world, and the 2022 conference in Philadelphia brought together more than 600 researchers and clinicians to discuss the most cutting-edge advancements in the field. Meanwhile, our NF Masterclasses (INFER) offer all medical professionals access to a series of educational lectures by leading NF experts. We also continue to improve our patient resources, including educational webinars, symposia, and informational brochures. 2022 saw the publication of revised diagnostic criteria and nomenclature for schwannomatosis, including *NF2*-related schwannomatosis (formerly called neurofibromatosis type 2). These changes will result in earlier diagnosis and better care for patients. We expanded our NF Clinic Network to include new adult clinics in Los Angeles and Little Rock, ensuring new and previously diagnosed patients have needed information and support.

Because NF knows no borders, we will continue to strengthen our global activities throughout Europe, Latin America, Asia, and beyond. To this end, we translated the NF Registry into five languages, with more to come. We are proud to inform you that 26 million euros from the European community have resulted in comprehensive platform trials for NF1 and schwannomatosis. We are ready to embark on its implementation in partnership with European colleagues.

World NF Awareness Day 2022 painted a clear picture of the reach of this community, as thousands around the world gathered virtually to watch our awareness day livestream, raising thousands of dollars for NF research. Our "Make NF Visible" and "Shine a Light on NF" awareness campaigns continued to attract more people to the cause. CTF Shine a Light Walk, NF Endurance, and Cupid's programs continue to flourish, providing more opportunities for the community to unite, grow, and raise funds for this fight.

I extend my heartfelt appreciation to everyone in this incredible community — the researchers, clinicians, regulators, industry partners, our dedicated Board, fundraisers, donors, volunteers, and our patients, their families, and caregivers. Together, we are in this fight, and only through our collective efforts will we emerge victorious. I want to say how grateful I am to all of you. Your vision of a world without NF has guided our drive to bring treatments to patients. I could not be more excited for what's to come.

Warmly and gratefully,

rell

Annette Bakker, PhD, President

Leading the Way

At the Children's Tumor Foundation, we're working to better the lives of more than 4 million people who live with some type of neurofibromatosis or schwannomatosis. We envision a day when patients can live their lives free of the pain and difficulties that come with nerve tumors, and our innovative team-based approach to drug development is making that vision a reality.

NF patients are told to "watch and wait" to see if their tumors will grow, and determine later if they will impact their lives with devastating conditions such as cancer. We don't think that's fair, and we don't think that's necessary. By bringing together the brightest minds in research and industry, and revamping the systems that often slow the pathway to treatments, we can change "watch and wait" to "here's what you can do." And the best part? CTF's research model not only benefits patients with neurofibromatosis or schwannomatosis, but also the millions of patients living with cancer, or one of the 7,000 rare diseases in existence.

We're in a rush to find treatments for all tumor types and all manifestations. Join us as we revolutionize how treatments are developed for those who need them most.

TRADITIONAL RARE DISEASE MODEL

TREATMENT

Why does it take so long and cost so much?

- Patient manifestations are unclear
- Clinical trial recruitment can be slow
- Disconnect between discovery and treatment
- Data is not shared and reporting is delayed
- Experts are isolated and knowledge is lost

CTF RESEARCH MODEL 생활

PATIENT

PATIENT

TREATMENT

GOAL: Double the speed for half the cost!

- Why are we faster?
- NF Patient Registry accelerates clinical trial enrollment
- Team science connects discovery to treatment
- Open NF datahub for real-time data release
- Preclinical platform accelerates drug testing
- Key opinion leader network speeds up decision-making

COST: Hundreds of millions of dollars

2023-2028 Strategic Plan

We envision a world without NF, and our strategic plan aims to make this vision a reality by driving research, expanding knowledge, and advancing care for the NF community. Historically, the Children's Tumor Foundation has laid a firm foundation for the critical work ahead by building NF awareness, education, and community. This has complemented a robust emphasis on NF research funding and the building of essential networks. **As we move forward, our unwavering focus is to lead and accelerate the innovation that ends NF.**

YESTERDAY Established Research &

Networks

TODAY Lead & Accelerate Innovation TOMORROV Develop Treatments - End NF -

INNOVATION PILLARS

Develop More Drugs - Expand the research field, develop panels of drug selection tools, double the number of R&D grants, and launch revolutionary projects.

Accelerate Treatments - Expedite the discovery of life-changing therapies with an innovative preclinical hub-and-spoke model, the ultimate all-in-one solution for pharma and biotech pioneers.

Strengthen Clinical Trials - Accelerate the development and approval of drugs being evaluated in clinical trial consortia and /or platform trials.

Empower Stakeholders - Enhance the understanding of NF and the NF Registry, increase patient participation, and train ambassadors. Expand the NF Clinic Network and the number of physicians and specialists who treat NF, including adult care.

FUELED BY

- Research & Data that is Patient & Clinician Informed
- Global Action and Inclusively in all Elements of our Support
- Action Over Talk: Be Assertive & Proactive
- \$130M Over Six Years: Prioritizing Innovation Leading Investments

Selu-bration

Koselugo (selumetinib), the first approved treatment for NF

In the spring of 2020, the U.S. Food and Drug Administration (FDA) announced the approval of Koselugo (selumetinib) for use in patients with inoperable plexiform neurofibromas, a common manifestation in neurofibromatosis type one (NF1). The FDA's approval of AstraZeneca's and MSD (Merck)'s submission was a major milestone for patients living with NF. Koselugo is the first-ever approved treatment for NF, and portends the potential for the development of more treatment options for all types of NF.

Koselugo's approval followed comprehensive clinical testing of the drug in patients at the National Cancer Institute (NCI), a division of the National Institutes of Health (NIH). In those clinical trials, over 70% of NF patients with inoperable plexiform neurofibromas saw tumor size reduction anywhere from 20–60% in size. In addition to both visible and actual tumor reduction, patients reported higher-quality physical function, reduced pain, improved mobility, and enhanced emotional and psychological status.

Many other MEK inhibitors are also now in clinical trials, including mirdametinib from SpringWorks Therapeutics, a company which the Children's Tumor Foundation helped spin off from Pfizer. CTF is also partnering with NFlection Therapeutics on a Phase 2b clinical trial with a topical MEK inhibitor for patients with cutaneous neurofibromatosis type 1.

Since the 2020 announcement, Koselugo has been approved for the treatment of NF patients in 32 countries. The AstraZeneca group of companies acquired Alexion, a global biopharmaceutical company focused on rare diseases. Alexion now distributes Koselugo throughout the world, adding to the growing list of partners working with the Children's Tumor Foundation to end NF.

Koselugo: Stories of the Road to Approval





60%

shrinkage

"People don't ask me what is wrong with my neck anymore. The drug does make me fatigued, which is tough since most kids my age are active in sports or physical activities that are challenging for me. But I've found activities that I enjoy, and friends that enjoy being a part of my life. I enjoy reading, gaming, boy scouts, coding, and more. I'm getting ready to start high school and I'm thankful for all the donors that funded the doctors and researchers who made selumetinib possible. Now that it is FDA approved, I am thankful that others may experience what I have experienced."

- NF Hero Philip Moss

SELUMETINIB: The Path to Approval

CTF research discovery paved the way to the first FDA-approved drug for NF.

NF Preclinical Initiative

The NF Preclinical Initiative (NFPI) began in 2008 as the NF Preclinical Consortium (NFPC), a five-year, \$7 million program that concluded in 2013. The NF Therapeutic Consortium (NFTC) continued the work of the NFPC, building on its infrastructure and discoveries.

Traditionally, it takes more than 15 years and costs hundreds of millions of dollars to translate a new discovery into one clinical treatment. The impact of the NFPI was clear: these teams completed 116 preclinical trials in 8 years, at a total cost of \$11 million. The preclinical studies led to multiple clinical trials, many of which are currently underway. One of those clinical trials included the MEK inhibitor selumetinib registration trial.

MEK Inhibitor Selumetinib...the road to the first approved drug for NF

Over 70% of the patient participants in a clinical trial of the MEK inhibitor selumetinib saw a reduction of 20–60% in the size of their inoperable plexiform neurofibromas. Brigitte Widemann, MD, of the National Cancer Institute, reported at the Foundation's 2015 NF Conference that response data in this trial for children and young adults showed meaningful decreases in tumor volume. This highly successful clinical study was the result of CTF's NF Preclinical Initiative, wherein Nancy Ratner, PhD, and D. Wade Clapp, MD, demonstrated that MEK inhibitors (MEKi) have a massive result on plexiform neurofibroma tumor volume in mice. The drug was first tested in a human subject as part of a Children's Tumor Foundation Clinical Research Award granted to Michael J. Fisher, MD, in 2011.

The Path to Approval

Selumetinib, a MEK inhibitor, was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) in April 2019. Previously, the treatment was granted Orphan Drug Designation by the US FDA in February 2018 and by the European Medicines Agency (EMA) in August 2018. The news that selumetinib was granted these designations was a giant leap toward the thrilling April 2020 announcement that selumetinib had received FDA approval.

Attracting Pharma

The Children's Tumor Foundation provides answers to the questions that pharmaceutical companies are asking in order to invest in a rare disease such as NF.

Are teams of scientists working on this problem?

CTF COLLABORATIONS AND TEAM SCIENCE INITIATIVES

The CTF research model values collaboration in every aspect of the drug discovery process. Diverse teams of experts managed by the Foundation collaborate and share their discoveries and data. By working together instead of in silos, we greatly increase the efficiency of research into problems that are too complex to be solved by individual scientists.

Are there enough care and treatment centers?

THE CTF NF CLINIC NETWORK IS CONNECTING DOCTORS AND IMPROVING CARE

A growing network of CTF-affiliated clinics is cultivating relationships between patients and doctors, and working to standardize and improve neurofibromatosis and schwannomatosis patient care.

Are there patients engaged in the drug discovery process?

CTF PATIENT ENGAGEMENT PROGRAM

Patients and caregivers are recruited to our patient engagement training program, creating a team of Patient Representatives who are knowledgeable in all aspects of NF drug discovery.

Are other investors interested in NF?

CTF AS IMPACT INVESTOR

CTF entered a new phase in its strategic NF research model by making a significant impact investment in a Phase 2b clinical trial at NFlection Therapeutics. This impact investment further establishes CTF as a co-investor with pharma/biotech in innovative NF research, expanding opportunities to increase the NF drug development pipeline.

Where do we find experts?

CTF'S KEY OPINION LEADER NETWORK

This expert network of specialists helps to guide drug discovery and development in order to increase scientific and clinical quality in decision-making.

Where can we find the patients to participate in clinical trials?

THE NF REGISTRY CONNECTS PATIENTS TO CLINICAL TRIALS

This patient-entered registry is structured to accelerate clinical trial recruitment, and fuels knowledge and understanding of the diversity of NF manifestations.

Where can we find new drug targets?

THE NF DATA PORTAL STORES OPEN DATA

Through our partnership with Sage Bionetworks, data is available and ready to use in the NF Data Portal. This centralized data repository is managed by specialists who collect, analyze, and release integrated data, accelerating the understanding of all types of neurofibromatosis and schwannomatosis, and the identification of "druggable" targets.

How can we standardize the endpoints of clinical trials?

THE REINS CONSORTIUM (Response Evaluation in Neurofibromatosis and Schwannomatosis)

This worldwide consortium of clinicians and patients develops new clinical trial designs, and works with the FDA to establish drug approval criteria.

Have these drugs been tested in animal models?

CTF'S NF PRECLINICAL INITIATIVE ESTABLISHED TREATMENTS FOR CLINICAL TRIALS

Because early testing of innovative concepts is vital, CTF has invested in teams of top laboratories with NF-relevant animal models, bringing promising drug treatments to the clinic quickly and efficiently.

Is there enough tissue available for testing?

THE NF BIOBANK PROVIDES TISSUE FOR RESEARCH

In order to solve the problem of a scarcity of relevant tissue to test, CTF created a centralized library of openly available samples for biomarker discovery and development, to support all aspects of drug research. This Biobank is now managed by the Indiana University School of Medicine's DHART SPORE program.

ANNUAL REPORT 2022 | 9

Driving Collaboration

Children's Tumor Foundation's Team Science Initiatives

INTUITT for NF2

The Children's Tumor Foundation partners with Takeda Pharmaceuticals and six leading medical centers on a clinical trial called INTUITT-NF2, an innovative platform trial that evaluates multiple treatments simultaneously. This initiative is a result of the landmark work of CTF's visionary Synodos for NF2 research collaborative, its NF2 Accelerator Initiative, an investment from Takeda Pharmaceuticals, the participation of scientists at the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH), and the vital Synodos NF2 leadership from Massachusetts General Hospital (MGH), Johns Hopkins University (JHU) and Indiana University (IU). This alliance across the academic, pharma, and patient landscapes has shortened the time from initial research to active trial, thereby bringing promising treatment options to the NF2 patients who need them.



Biomarker Project for NFI

In 2022, the Children's Tumor Foundation announced a groundbreaking three-year study, which it will fund for nearly \$2 million, to determine if a DNA-based blood test can offer better understanding and ultimately earlier diagnosis of malignant peripheral nerve sheath tumor (MPNST) predisposition in NF1 patients. CTF has committed its support to fund the study in its entirety. The project format is inspired by CTF's highly effective Synodos model, which brings top researchers together to solve complex problems in an open and collaborative environment.

Optic Pathway Glioma Multicenter Study

The Children's Tumor Foundation and the Children's Hospital of Philadelphia (CHOP) have renewed their five-year study of optic pathway glioma (OPG) in children with NF1. The study involves 25 NF clinics, and aims to provide clinicians with clear criteria that will help them decide when a patient should be treated, and when treatment (such as chemotherapy) should be avoided. OPG develops in 15–20% of children with NF1, and can cause significant health issues. In 2022, the study was renewed, and renamed to memorialize late CTF ambassador Jeffrey Owen Hanson, who suffered from OPG.

Synodos

Synodos is the premier collaborative research model of the Children's Tumor Foundation, and has represented a significant financial commitment on the part of the Foundation. In each Synodos collaboration, CTF assembles "dream teams" of doctors, scientists, and patients who work together to solve problems that are too complex for any individual lab or researcher to solve. Our goal is to speed the drug discovery process through innovative research methods, collective knowledge, and data shared openly through CTF's NF Data Portal. This data is analyzed by our partners at Sage Bionetworks, and is then made available to the rest of the world. This approach is expanding interest in NF research to additional fields, including cancer.

Building on Past Success: Synodos for NF2

The first of the Synodos models established by CTF, Synodos for NF2 launched in 2014 to provide clarity to patients about available drug options, and completed its work in 2018. This consortium of multidisciplinary investigators from 12 world-class labs and medical centers performed rigorous drug testing that laid the groundwork for further research and clinical trials currently in progress for the treatment of NF2-related schwannomatosis.

Building on Past Success: Synodos for NF1

CTF sought out the concerns of NF1 patients when establishing Synodos for NF1, a team-science initiative that began its work in 2016 and concluded in 2020. Patient concerns for better treatment options for NF1, as well as answers for low-grade glioma patients, prompted CTF to initiate three separate consortia, bringing together 24 investigators from eight leading institutions and two companies.

Building on Past Success: Synodos for Schwannomatosis

An international consortium of clinicians and scientists from multiple disciplines made up the Synodos for Schwannomatosis team. In 2021 the project completed the work of performing an extensive molecular analysis of schwannomatosis tumor samples to identify new therapeutic targets and advance the understanding and management of the disease, with a special focus on pain.

Fueling Discovery

CTF Discovery Fund

The Children's Tumor Foundation Discovery Fund for NF Research funds more than \$3 million in research grants each year, and accelerates drug discovery. This initiative is set up to attract and invest in the best and brightest minds, who will advance our goal of bringing new treatments to patients faster and more efficiently.

The Young Investigator Award (YIA)

The YIA is the Foundation's oldest research award program and serves to advance understanding of the biology of all types of neurofibromatosis and schwannomatosis, and brings young researchers into the field. This award program is one reason the understanding of NF has grown so rapidly. Many of CTF's past YIA awardees have gone on to pursue lifelong careers in the field of NF research.

ry Initiative (DDI)

The CTF Drug Discovery Initiative (DDI) program aims to stimulate NF drug discovery by funding researchers proposing to investigate novel or repurposed therapies for NF or to develop tools that support such research. The goals of the DDI program are to support early-stage testing of therapeutic compounds for the treatment of NF, or to support the generation of new *in vitro* or *in vivo* model systems. CTF has awarded more than 70 DDI awards since the inception of the program in 2006.

g Discovery Initiative istered Reports (PDI-RR)

In 2017, CTF and the scientific journal PLOS ONE launched a funding program called the Drug Discovery Initiative Registered Report (DDIRR) Awards, which evolved from the DDI program and was a funderpublisher partnership that guaranteed its awardees with an in-principle acceptance to publication in the journal PLOS ONE, regardless of study outcome.

Clinical Research Award (CRA)

The Foundation's Clinical Research Award program supports early-stage NF research involving human subjects. These awards encourage studies of candidate therapeutics or other interventions and treatments; clinicaltrial-enabling or ancillary studies; natural history studies; and investigations into clinical care in NF.

FI Gene Therapy Initiative

The NF1 Gene Therapy Initiative has the objective of exploring the feasibility of gene editing as a potential therapeutic strategy for NF1. This initiative aims to support proof of principle *in vitro* studies to investigate the feasibility of genome editing techniques, including but not limited to those based on CRISPR-Cas9, to correct pathogenic mutations in NF1 gene.

Contract Awards

The Contract Awards are special awards that the Foundation assigns to academic researchers or for-profit entities to run specific projects. The Contract Award is not a typical award but rather an objective and task-oriented project that allows the recipient to access funding otherwise not obtainable through other grant mechanisms. We would again like to thank you and all those who donated to CTF, for believing in our projects and funding our CRAs. We are proud that our CTF awards have now produced over \$5 million in federal research grants.

— Drs. Rob Avery, Michael Fisher, and Gena Heidary

Accelerating Innovation

NFX-179 Impact Investment

The Children's Tumor Foundation entered a new phase in its strategic NF research model by announcing a significant impact investment in a Phase 2b clinical trial at NFlection Therapeutics, a biotechnology company focused on the discovery and development of effective, targeted therapies for rare diseases. The trial involves NFX-179, a topical (on the skin) treatment which has successfully passed a Phase 1/2a (safety and first signs of efficacy) trial. The NFX-179 treatment is for cutaneous neurofibromas (cNF), which are tumors that grow in the skin or right underneath the skin, and result in severe, disfiguring bumps on the skin.

CTF's investment strategy in NF drug development is a diversified portfolio approach to tackling all forms of NF, from early-stage investments in young investigators, open data collaboratives such as Synodos. This first-inits-history impact investment further establishes CTF as a co-investor with pharma/biotech in innovative NF research, expanding opportunities to increase the NF drug development pipeline.

NF2 Accelerator Initiative

This powerful initiative is bringing treatments to the clinic (and patients) by expanding the clinical drug pipeline for NF2, improving drug selection through the development of innovative testing models, and the development of gene therapy options that address the underlying genetic causes of NF2-related schwannomatosis.

As a global leader of NF research, the Children's Tumor Foundation is dedicated to developing cures for all forms of NF. The Foundation and its partners bolstered the NF2 research field through team science with Synodos for NF2, bringing together multidisciplinary scientists from 12 world-class labs. That collaborative effort resulted in the identification of promising new clinical candidates for NF2. The NF2 Accelerator Initiative leverages this new knowledge into a new and ambitious structure, with the goal of speeding up the drug discovery process.

Strategic Partnership: Deep Science Ventures and Cancer Research Horizons

The Children's Tumor Foundation has joined an alliance with Deep Science Ventures, a London-based venture creator, and Cancer Research Horizons, Cancer Research UK's new innovation organization. Together these groups will power the creation of cutting-edge ventures in oncology, with CTF acting as a strategic partner to aid efforts in identifying possible venture-creation opportunities in NF.

Focused Ultrasound Foundation and CTF Partner on NF Study

The Focused Ultrasound Foundation and the Children's Tumor Foundation have established a partnership to advance innovative, noninvasive treatments in pediatrics. For more than 15 years, the Focused Ultrasound Foundation has been dedicated to advancing the development and adoption of focused ultrasound. To launch the partnership, the organizations are co-funding an early-stage laboratory study to investigate focused ultrasound's role in addressing *NF2*-related schwannomatosis.

Genotype-Phenotype

Research funded by CTF's Isaac and Sadie Fuchs Genotype-Phenotype Grant found that certain NF1 genotypes can help predict phenotypes. Led by Ludwine Messiaen, PhD, of the University of Alabama at Birmingham, this discovery of genotype-phenotype correlation can impact counseling and management of more than 10% of the NF1 population.

The BRIDGE Initiative

"oT

The Children's Tumor Foundation has joined forces with the Milken Institute's FasterCures and CureSearch for Children's Cancer in a collaborative effort called the BRIDGE Initiative, which aims to convince pharmaceutical and biotech companies to release discontinued but valuable medicines. The BRIDGE Initiative is committed to unlocking these drugs for intended or new indications, such as for NF.

NF Diagnostic Criteria Workshops

In 2017, a group of NF investigators reached out to CTF to sponsor a revision of the NF diagnostic criteria, sparking a multi-year process that involved more than 90 leading NF experts from around the globe. In May of 2021, an update to the diagnostic criteria for NF1 was published in Genetics in Medicine, the official journal of the American College of Medical Genetics and Genomics (ACMG). An update to the diagnostic criteria and nomenclature for NF2 and schwannomatosis was announced in the same publication in early 2022. These updates reflect the tremendous increase in knowledge about these dconditions, and will allow for earlier and more accurate diagnoses for patients.

NF Variant Curation Panel

The Children's Tumor Foundation has funded a ClinGen (Clinical Genome Resource) driven initiative to build a central resource that defines the clinical relevance for all NF gene variants (*NF1, NF2, SMARCB1, LZTR1, SPRED1*) for use in precision medicine and research. The expert panel is composed of 25 experts among molecular and clinical geneticists, genetic counselors, and other experts in NF from 9 countries and 18 different institutions.

NF Conference

The annual NF Conference attracts clinicians, researchers, industry representatives, and patient advocates, in person and virtually, who are interested in hearing about the most recent advancements in research and clinical care for neurofibromatosis and schwannomatosis. The event is a critical forum for consensusbuilding and advancing basic, translational, and clinical research in NF and related fields, while fostering collaborations within and beyond the NF community. In 2022 the NF Conference convened in Philadelphia, Pennsylvania, and more than 600 attendees were presented with the best and latest research and clinical care practices. In addition to the core agenda, attendees were able to view poster presentations while a panel of judges selected the top three submissions from clinical and basic science entries. The meeting wrapped up with the presentation of the 2022 Friedrich von Recklinghausen Award, awarded to Jaishri Blakeley, MD, of Johns Hopkins School of Medicine.

NF Hackathon

The Children's Tumor Foundation hosted its fourth Hackathon, the HACK4NF, in late 2022. The goal of this virtual hackathon was to advance research for all types of NF by utilizing genomic datasets to develop drug targets, predict NF variants and correctly classify NF tumors. More than 300 people from diverse fields participated in the HACK4NF, including those with expertise in computational biology, predictive AI, genomics, data analytics, and medical research.

CTF in Europe

Children's Tumor Foundation Europe is a medical research NGO that serves as a partner organization to CTF in the United States. Throughout its history, CTF has funded the best and most promising research globally, regardless of location, and as a result many European laboratories and clinicians have benefited from CTF support. Children's Tumor Foundation Europe is further strengthening the bonds between experts and research opportunities worldwide, in line with CTF's emphasis on open collaboration and open data.

The focus of Children's Tumor Foundation Europe is to raise awareness of NF at the European level, and build relationships with European agencies and partners, including EFPIA (European Federation of Pharmaceutical Industries and Associations) and the EMA (European Medicines Agency, the European equivalent of the FDA), while maintaining its commitment to funding and driving innovative research worldwide that will result in effective treatments for NF.

In 2022, the Children's Tumor Foundation Europe further focused on the consolidation of European clinic networks, the organization and planning of INFER (International NF Educational Resources) masterclasses for healthcare providers, and provided travel grants to medical professionals for their training in European NF excellence centers, as well as training to European researchers to allow them to

successfully apply for grants issued by US funding bodies. CTF also continued to work at the expansion of the NF Registry in Europe in partnership with national patient associations.

CTF and 35 other organizations joined together in a project called EU Patient-cEntric clinicAl tRial pLatforms (EU-PEARL), a unique public-private strategic partnership funded by the Innovative Medicines Initiative to conceptualize and lead the design of integrated research platforms, enabling a more efficient and patient-centric drug development in Europe. CTF is the co-leader of the neurofibromatosis package of this exciting project, where NF is serving as a test case for rare diseases in general.

ය්පි

NF EDUCATIONAL RESOURCES

A series of online educational lectures for medical professionals by leading NF experts

Sustaining Hope

NF Summit

The 2022 inaugural NF Summit was an educational and networking conference that evolved from CTF's annual NF Forum and Volunteer Leadership Conferences, which have taken place for over a decade. Those annual meetings built the necessary foundation for a new, dynamic, inclusive event intended for anyone with a connection to NF. The NF Summit brought together over 50 speakers covering a wide range of content, including chronic pain, hearing loss, and using social media to raise awareness and build community. Of those speakers, community at a CTF event. Community Recognition Awards (The Make NF Visible Community Awards) were presented to volunteers, clinicians, researchers, corporate partners and community members who strive to make NF visible in various ways and who are true champions of the Foundation and the NF cause

NF Clinic Network (NFCN)

18 . Vien

The NF Clinic Network was established by the Children's Tumor Foundation to standardize and raise the level of NF clinical care, and to integrate research into clinical care practices. The NF Clinic Network (NFCN) has grown to 69 clinics in the US and Canada that serve almost 20,000 patients each year. Clinics may apply to join the NFCN and are evaluated based on several factors, including NF expertise, patient volume, multidisciplinary approach, commitment to NF education and training, research activities, and connections with the Foundation.

WWW.C

Patient Engagement

The Foundation's Patient Engagement initiative is designed to prepare individuals with NF and their families to participate as advocates in NF research. Patient Representatives are trained to work with stakeholders such as researchers, the pharmaceutical industry, and the U.S. Food and Drug Administration to add their perspectives during all phases of the research process. In 2022, the Children's Tumor Foundation took the opportunity to examine the broader potential for patient engagement in the field. As we move into 2023, CTF is excited to build on the success of the past several years with a newly designed patient engagement initiative called CTF Engage, which promises to elevate the patient voice in research in even more impactful ways.

NF Camp

TF.ORG

More than 100 teens and young adults attend CTF's annual NF Camp each year. NF Camp takes place at the beautiful Camp Kostopulos in Emigration Canyon, Utah, with ropes courses, horseback riding, and more. Attendees participated in games, kitchen takeovers, arts and crafts, and laughter. Campers were able to come together to talk freely about their NF journeys, share their experiences, and make lasting friendships.

NF Registry

More than 11,000 individuals have joined the Foundation's NF Registry, making it the largest patient-entered database of people with NF, and the only one designed to be available to all interested investigators. The Registry has proven to be a valid and useful tool for both patients and researchers, according to an analysis published in the journal *PLOS ONE*. Not only are thousands of patients from all over the world contributing their data online at nfregistry.org, but the data is being actively used—and appreciated—by researchers working on all forms of NF, as well as attracting the attention of pharmaceutical companies. The Registry is now on the OpenApp platform, which has made the site easier to use and allowed it to be translated into multiple languages, further increasing participation.

Over the decades, this organization has done more to advance care of families with NF than any other U.S. organization, and it has not lost sight of the importance of interactions between individuals with these conditions, as exemplified at NF Camp. CTF truly enhances my care of families dealing with all issues related to NF.

— David Viskochil, MD, PhD, University of Utah

Spreading Awareness

CTF's marketing, communications, and advocacy efforts support patients and their families no matter where they are on their NF journey. Whether newly diagnosed, in the midst of a treatment regimen, or engaging with the broader community to improve awareness and understanding, patients and families can rely on CTF for the latest information about all types of NF.

All too often the patient journey starts with an online search that leads to inaccurate or outdated information, and so the Children's Tumor Foundation prides itself on being a safe haven for all who need direction and support. We provide up-to-date NF knowledge on our website and in our patient brochures, newsletters, webinars, and videos. We also drive a dynamic and engaging presence on social media, connecting patients and families worldwide, and ensuring that those who don't have NF support in their community can find it through the global CTF family.

In a world that runs 24/7, the Foundation breaks through with impressive media outreach and public relations efforts that spread the message that NF is important and that NF patients deserve support for bettered lives. Our multichannel approach in print, digital, TV, and radio results in hundreds of media pickups each year, and brings the NF story to hundreds of millions of people worldwide.

While NF is a serious condition, the Foundation creates inspirational and engaging tools that patients can use to share their NF story in a personal way. From "I Know a Fighter" to "Shine a Light on NF" to "Make NF Visible," we make sure that everyone knows our driving passion: to END NF.

The Foundation's "Make NF Visible" campaign draws attention across the globe to those living with NF. MakeNF Visible Children's Tumor Foundation

Making NF visible cultivates community, connection, and deep friendships with others just like you.... By ourselves, we can only go so far, but together we can go even further.

- Nissa Novas, who lives with NF2

The "Shine a Light on NF" initiative cast a blue-and-green glow on hundreds of buildings, bridges, monuments, and family residences across the country and around the globe.

Thanks for donating

r Helki Pruitt

uitt Kathryn Gardner

Make<mark>N;</mark> Visible

A FIGHTER.



To Make a Donation Text ENDNF to 41444

#EndNF

an to donate

PROCLAMATION

For the third year in a row, May 17 World NF Awareness Day was celebrated during a live virtual event, which featured numerous celebrity appearances and stories from NF Heroes, and raised funds for NF research.

Proclamations were issued in state houses and city halls across the country recognizing "NF Awareness Month." CTF volunteers engaged with their local leaders and helped ensure that more people in office know about NF and how it affects their constituents.

Raising Funds

Special Events

The CTF Special Events team works with volunteer committees across the country to organize festive fundraising galas, golfing tournaments, cocktail parties, and Dancing With Our Stars events. Meanwhile, "Fight NF Your Way" volunteers organize one-of-a-kind fundraising events, including comedy nights, fashion shows, and sweet tea stands that help fund NF research.

SHINEON

EON

HIGH

Shine a Light NF Walk

Shine a Light NF Walk is the signature fundraising event of the Children's Tumor Foundation, bringing NF out of the shadows and inspiring the community to come together to raise critical funds for NF research. At these fun and inspirational events held across the country, communities rally around local families affected by NF. Frequent appearances of costumed characters, balloon animals, and face painting bring bubbling energy from start to finish. The 2022 Shine a Light Walk season included 4,600 participants and raised \$1.53 Million to further NF research.

Cupid's Undie Run

Cupid's Undie Run is a mile(ish) fun run in which brightly adorned, underwearclad team members run outdoors for NF awareness and to raise funds for NF research. The first Cupid's Undie Run took place in 2010 in Washington, D.C. What started as a unique "let's put hilarity into charity" twist on traditional charity walks/runs turned into a national phenomenon attracting wide attention and increased funding for NF. In the decade since, Cupid's Undie Run has raised millions of dollars for CTF-funded NF research.

NF Endurance

The NF Endurance Team is a global community of individuals challenging themselves to go the extra mile to end NF. Inspired by individuals with NF (our "NF Heroes"), NFE athletes run, bike, hike, and swim in endurance events around the world while raising critical research funds for NF. From first-time 5K runners to triathlon competitors, all NF Endurance team members are in pursuit of the same goal: to one day end NF.

Advocacy

From the earliest days of the Foundation, CTF staff and volunteers have advocated relentlessly for continual federal funding of NF research, with frequent and highly strategic visits to Capitol Hill and Member District Offices. The CTF Government Affairs Team continually expands the breadth of its advocacy and profile-building efforts with the guidance of outside counsel Squire Patton Boggs. We are also actively engaged with the Defense Health Research Consortium. This Consortium is composed of over 50 organizations dedicated to the preservation of annual funding levels for Congressionally Directed Medical Research Programs (CDMRP) within the Department of Defense.

Our voices are being heard! In 2022, because of continued strong advocacy work from the Children's Tumor Foundation and the NF community, bipartisan leadership in Washington, D.C., included \$25 million for NF research through the CDMRP for Fiscal Year 2023. This funding supports strategic research resulting in new discoveries and better outcomes for NF patients and families, and will allow us to further develop scientific data, break through barriers, and forge a pathway to end NF.

National Ambassador Eddie Purtell

To quote the great Vince Lombardi, 'It's not whether you get knocked down, it's whether you get up.' Anyone with NF will have to deal with some difficult situations, so no matter how many times you get knocked down, always remember to get up and keep fighting.

— Eddie Purtell

Eddie Purtell was diagnosed with NF at just one-month-old. By the time Eddie understood what it meant to have NF, he had already undergone several surgeries and had his left eye removed due to an optic nerve glioma behind the eye.

Since then, he has had over 20 procedures but has never let that stop him from achieving all he has. His parents recall that Eddie has always been fearless through all that he's experienced. He lives his life to the fullest, determined to prove that having NF does not have to stop him from enjoying life. From skiing to soccer to lacrosse, Eddie enjoys being active and playing sports. His love of sports led him to start running marathons, and he has since run 14 half marathons, 11 of which have been to raise money for the Children's Tumor Foundation. With these efforts, he has raised more than \$180,000 to find a cure for NF and is still going strong.

On top of that, he is also involved in the Children's Tumor Foundation's Volunteer Leadership Council and Junior Board.

Eddie was honored as the 2022 National Ambassador at the CTF National Gala, an award recognizing courage living with NF and personal efforts to further the Foundation's goals of research, public awareness, and patient support.

Despite the challenges of NF, Eddie has graduated college, is working a great job, has run multiple marathons, and serves as a role model for others. He hopes that his contributions will help make life easier for young kids with NF and that he can inspire those children.

Financial Summary

Expenses 2022

8% Fundraising Management

59%

Research & Medical

85%

6%

Public Education & Patient Support

_				
	Operating support and revenue			
		2022	2021	2020
	Contributions: individuals	\$8,136,795	\$8,071,808	\$5,943,186
	Contributions: corporations and foundations	\$3,951,038	\$4,035,129	\$3,310,653
	Bequests	\$306,122	\$185,000	\$580,538
	Contributed goods	\$226,605	\$214,955	\$17,684
	Other income	\$1,252,318	\$1,539,709	\$995,628
	Government grants	\$299,188	\$1,077,026	\$691,400
	Loss from disposition of property and equipment	(\$9,445)	0	0
	CONTRIBUTIONS AND OTHER INCOME	\$14,162,621	\$15,123,627	\$11,539,089
		2022	2021	2020
	Special event revenue	\$2,970,370	\$1,818,650	\$1,084,549
	Less: direct benefits to donors	(\$222,968)	(\$40,000)	(0)
	Special event revenue, net	\$2,747,402	\$1,778,650	\$1,084,549
	TOTAL OPERATING & SUPPORT REVENUE	\$16,910,023	\$16,902,277	\$12,623,638
	Operating expenses			
	Program Services	2022	2021	2020
	Research and medical	\$9,468,472	\$6,032,140	\$6,326,821
	Public education and patient support	\$4,122,574	\$2,720,523	\$2,337,711
	TOTAL PROGRAM SERVICES	\$13,591,046	\$8,752,663	\$8,664,532
	Supporting Services			
	Management and general	\$1,144,982	\$945,320	\$904,881
	Fundraising	\$1,266,163	\$930,453	\$815,402
	TOTAL SUPPORT SERVICES	\$2,411,145	\$1,875,773	\$1,720,283
•				
	TOTAL OPERATING EXPENSES	\$16,002,191	\$10,628,436	\$10,384,815
	Change in Net Assets from Operations	\$907,832	\$6,273,841	\$2,238,823
	Other changes	2022	2021	2020
	NON-OPERATING REVENUE	(651,650)	\$561,848	\$532,959
	and the second sec	and the second second		
	Change in Net Assets			
		2022	2021	2020
	Net Assets, beginning of year	\$27,295,800	\$20,460,111	\$17,688,329
	Net Assets, end of year	\$27,551,982	\$27,295,800	\$20,460,111

WithThanks

The Children's Tumor Foundation is grateful for the continued support of the many individuals, corporations, foundations, and communities who have joined us in the fight against NF. Thank you for your help in advancing the Foundation's mission.

Architects of Impact

DISTINGUISHED BENEFACTORS \$1,000,000+

Frank & Shelley Haughton Laurée Moffett NF Forward The Wonder Fund

PRESIDENT'S COUNCIL \$500,000 - \$999,999

Sally Gottesman Richard Horvitz & Erica Hartman-Horvitz

Distinguished Donors

FOUNDER'S CIRCLE

\$100,000 - \$499,999 Estate of Michael J. Ahern Alexion AstraZeneca Rare Disease Anonymous **CDCM Morgan Foundation** Facebook Jerome & Debbie Falic **The Falic Family Foundation** Gabriel Groisman & Lisa Falic-Groisman The Estate of Patricia Ann Herrmann **Rick & Amanda Jaffa** Dawn & William Jones **Richard & Leslie Kates** Kevin & Elizabeth McMeen **Oregon Community Foundation** Leslev & Constantine Oslica **Michael & Kelly Peterson** SpringWorks Therapeutics, Inc. Stuart Suna **Roland & Nicole Thoms Rachel Tiven & Seth Marnin**

FELLOWS

\$50,000-\$99,999 Elaine & Edward Altman Jake & Elizabeth Burke Penny & John Burkhalter

Davis Charitable Fund Bernard F. and Alva B. Gimbel Foundation **Marilyn Harrison RB & Susan Harrison Frances Kallman** Jon & Paige Kayyem **KBF Foundation CANADA** Stephanie & Jake Keet Lamar Advertising Steven & Alvson McKenzie John & Beth Morris **Neurofibromatosis Therapeutic** Acceleration Program (NTAP) at Johns Hopkins University School of Medicine **NFlection Therapeutics, Inc. Carolanne Owenby** Jeffrev & Diane Owens **Recursion Pharmaceuticals** Nancy Roberts Mitchell & Liz Rodbell Catherine & Brian Shaw Dong & Lisa Shen **Richard & Faye Soll** Love, Tito's **Thai Trower** Varsity Painting, Inc. Clara & Scott Wilpon Xi Xiao

CHAMPIONS

\$25,000-\$49,999 **Iris & Richard Abrons** Beau Acuff **Daniel & Robin Altman** Nancy Colaw Eric & Mia Colodne Jon & Fran Cone The Derfner Foundation **Dove Givings Foundation Tracy Galloway** Tara Gartman Amanda & Joseph Gentile **Kristin & Nicholas Guehlstorf** Jane & John Hunter Jerry & Maureen Hunter Little Heroes of North Georgia LLC Vicki Match Suna **David & Cindy Metrikin** Stephen & Eve Milstein Erin & Shahan Mohideen Calvert Moore Lara Mukabenov Nomad Framing, LLC **Rachel & Dustin Patterson** Laura Pells Penny's Flight CTF Initiative Acquavella Family Foundation Jennifer Creel **Charles Daniels**

Chad & Kate Doerge Christina Lari Marv Reed Nancy Spofford Yerkes Foundation Mary Alice Stephenson Andrew Walter Weekes Family Foundation **Roger Widmann** Anthony & Laura Perfetti **Benjamin & Tammy Phipps** Eddie Purtell **Ross & Cristin Rhinehart Roberts Family Douglas Roberts Bruce & Joy Roberts** Craig, Flori, & Alex Roberts Kurt & Judith Ross Jessica & Brett Samblanet Jack & Marjorie Schillinger **Family Foundation** Phil & Judy Shwachman for **The Shwachman Family Fund Barry & Patricia Simon** Sissy's Log Cabin Patricia Spencer The Spiegel Family Foundation Tyler & Alicia Tegtmeyer Megan Thynge **Marjorie Tiven**

James Thoms Donn & Angela Vanderploeg Robert & Pamela Willis Debbie & Richard Wilpon Fred & Judith Wilpon Robert & Terry Yanowski Zisson Foundation

ADVOCATE

\$10.000-\$24.999 Amazon.com, Inc. Anonymous **Rudy Arietta Marie Artim** Michael & Ali Ball **Donald H. Baltzer Trust Eileen B. Baltzer Trust Diane & Hubert Barksdale** Jason & Julie Baruch **Michael & Shaun Beckish Brian & Kelly Behrens Dan & Dorothy Bell** John & Julie Benton Makayla & Trynon Bigham **Greg Bloom & Suzanne** Jaffe Bloom **Ariana Bloom Noel & Jamie Brabant Nick Bradley-Hole** Robert Brainin & Nicola Kean The Broder Family Foundation Inc. **Bill & Candee Brooks Dominic & Hayley Brown** Colin & Sarah Bryar **Danielle Buglino** Kevin Cahn Barbi Carignan Scott & Kelly Carpenter James & Erin Chimento **Olivia Christovich** William and M.L. Christovich **Charitable Foundation, Inc. Charlotte Clymer** Tammy & Yaakov Cohen Michael & Jayne Cohill **The Colin Courageous** Foundation, Inc.

Jason Colodne & Colbeck Capital Management Todd Constable & Kristina Rath **Corner Foundation, Inc. Cromwell Harbor Foundation** Mark & Deanna Daus **Caroline Fabian Davis & Brandon Partridge Jules Demchick & Barbara** Nissem Ian & Chelsey Desmond Nicole & Andy Domazos Hannah & Lindsey Duby Cody & Mike Duley Amanda & Evan Dumas **Guillaume Dumas & Leslie Weiss Patrick Andrew Dunigan Michael Elder Deborah & Richard Estabrook Elizabeth Fennell Daniel & Debra Fontaine** Joshua & Deborah Freitas **Daniel & Sandra Frenia** Hiroshi & Misako Fujisaki **The Gallagher Family Foundation McKinnon Galloway** Eli Jake & Eva Gelb **Clifford Gelbard Daniel & Ruth Georgi** Mahmood Ghassemi Gary & Jeanne Glodek Stuart & Marcey Goldner John Golfinos Matthew & Jamie Goode **Beth Grindle** Gary & Cari Gross **Gwatney Buick GMC** Kiley & Andrew Hamor Shaun Hansen & Ilse De Bruin Hauske Family Foundation, Inc. Healx Jason & Janine Henahan Maureen & Kevin Hussey **Tony & Annette Isaacs Stephanie & Drew Jennings** Jersey Mike's Eric & Mary Beth Johnson Sarah Jordan & Suresh Nagappan

JTJ Restaurants Alex Kates & April Ondis Jenny & Jared Kearschner Marla Khetem Scott & Michelle Kosinski Krewe of Alex, Inc. Lloyd & Lois Lambright Linda Landis Jeffrey & Randi Levine Adam Levine Liang Kung Lin & Jane Chiang Lin Peter & Angela Lindeback Stephen & Catherine Lorberbaum Gregg & Linda Macmillan **Tonya & William Magill** Linda Martin Liz & Dave Martin Rose Match Suna Ted & Jeanette McGee Kristin Meek Surbhi Mehta Rodrigo & Luz Mejia **Metro Management Development Co., Inc.** Carolyn Meyer-Tolliver **David Miley** Stephen & Cynthia Miller James & Cathy Moore **Bruce & Wendy Mosler Caroline & Chris Moulsdale Brandon Munson M.W. Murphy Foundation** Harvey & Joan Newman David & Sara Nimmons **Ryan & Kristy Nobles** Lindy O'Neal Kay & Terence O'Neill Michael & Sara Orlando **Dustin & Jill Ostrom** Matthew & Emily Parker James & Mariellen Paulus **Gayle & Roger Peper** Tandy Wolters & Michael Peper **Deanna Pittore** Scott Plotkin & Candace Lun Plotkin **Tony Plush**

Christopher & Mary Joyce

Tom & Winnie Polen Jeffrey & Rubi Powl Amanda & Carl Pregler **Ned & Peggy Purtell R. Simpson Gifting Fund** David & Staci Raymond **Amy Reay** Antonio & Emanuela Rillosi **Carson & Tawnya Ripple** Lisenne Rockefeller Dan Roda & Elizabeth Michael Tara & Cale Rogers Jennifer & Dan Rubert **Kenneth Rudd** Scott & Amanda Rudnick **David & Cindy Rulon David & Linda Sassa Priscilla Saunders** Jen & Brad Schneider Sei Bella Med Spa Fraser & Rosemary Seitel **Carolyn Setlow & Andrew Shapiro** Tony & Andrea Sirchio **Richard & Gail Sobel** Jennifer & Timothy Soliman Peter & Connie Sorman **Squire Patton Boggs** Steve Madden Ltd. **The Stewart Charitable Foundation** Alan & Joanne Suna Pete & Lynn Tanguay **George Thuronyi** Jacob Thyberg **Charles & Kimberly Thyberg Stephen & Stephanie Timmons Gabrielle Tiven Emily & Nicholas Tseffos** The Tudor Foundation, Inc. Nicole Ullrich & Mark Johnson **Priscilla Watkins Emily Anne Weikert Charitable** Foundation Antonio & Amanda Williams Wireless Zone Gives Alex & Kristin Zisson

Donors

SUPPORTER \$5,000-\$9,999

Nicole & Luke Abbate Jason Ackerman & Jessica Smagler Star Akel Ellen & Dustin Anderson Deborah & James Andrychuk Michael & Jennifer Antonaccio Ascentist Physicians Group Aspen Insurance Justin Astorquia Natalie & Mark Atkinson B The Difference Christine & John Bakalar Elizabeth & Jordan Bamesberger Nicole & Donald Banach Alvin H. Baum Family Fund Craig & Suzanne Baumann Claudia Becerra Berkowitz Family Foundation Beta Sigma Phi Robert Bierman & Melanie Prakuson-Bierman Alex & Cameron Bingham Bourbon Charity Ellen Block Bob's Discount Furniture Charitable Foundation, Inc. Joseph & Nikki Boros **Branca Family Foundation** Charlotte & David Bray Phil Brooks Andrew & Laurie Brotman The Brown Foundation of Little Rock Bruce Oakley Inc Glen Bruemmer Family Foundation Bud Agency/Bark Bar Anthony & Camille Burke **Burkhalter Technologies** Robert & Barbara Byrne Beatrice & Max Caito Jefferson Simon & Tracy Camaj Catherine & Terry Cammon Kristen Campilonga Jacquelyn & Scott Cardenas Louis N. Cassett Foundation Chad Chance Megan & Ryan Christie Christopher & Morgan Clayton **Cline Construction** Leann & Bill Colaw

David Colleran James Cooper Kenneth Cooper Anne & Thomas Cox Colby & Melanie Cox Naomi & James Cuka Gerry & Vanessa Dangoia Jeffrey & Wendy Dankey Datamax Inc. Benjamin Davey Dwight & Cheryl Davidson **Timothy Davis** Jeannie & Derek Dehne Tony & Nancy Disser Kevin & Shelley Doane Estate of Tevyen Dorfman Timothy & Sheila Drevyanko Jeremy Dykes James & Suzanne Earle Mark & Kimberly Earle Brian & Kelly Eastman Terri & Chuck Erwin **Evening Membership** Department of the Haddon Fortnightly Facets of Fire Patricia W. and Alfred E. Farah Charitable Gift Fund Faucett Freak Show Deborah & Douglas Feist Jonathan Flaherty Forst Foundation Mark Fowler & Jessica Kaplan Rita and Fred Family Fund Julie & Jonathan Fritz G&F Group Jennifer & Michael Gargano Roberta Gelt Christopher & Summer Gibson Paul Gill Margaret & Thomas Gordon Anita & Thomas Gribben ludit Groisman Lauren & Brandon Gross GTL Americas LP Lisa & Daniel Gutierrez Hackers For Vets Bettina Hammond Matthew Hard Rachel & Buddy Harding Jessica & Mark Hardwick Sarah Ellen Hart Matthew & Nora Hay John & Michele Holbrook Michael Horlick, Sr.



Richard Howard Richard & Nanvy Howe Kevin Hurley Insperity Inspirant Group Ιημνο Jav Franco and Sons Inc. Stephanie Jaramillo & William Karabell Jesse & Tyler Jenner John and Nellie Bastien Memorial Foundation Chris & Jennifer Johnston Jason Jones Bill & Sharri Jones Brandon & Jessica Karasek Carrie Keagler John Kellv Jeremy & Amanda Kent John Kiczek & Christine Seuffert **Kilpatrick Family** Eric Kimmel Lauren & David Koplowitz Sean Kosney

Robin Kramer & Albert Behler Becky Krurnowski Landers Auto Group Langan Engineering Mike & Kelly Laughlan Beniamin Leathers & Kathleen Hatcher Mike Lee Alice & Zalman Lekach LG Ad Solutions Marcia Likarish Laura & Kenneth Linkous Scott & Allison Lissner Anne & Sonny LoConte Debra Lynch-Sorber Joshua & Andrea Marian Courtney & David Marshall Ariel Martin Tom Martindale Robert Mason Randy & Sasha Match-Sloan Miranda & Rod Mcmanus Jessica & Joseph McQuillan The MHE Foundation, Inc. **Flizabeth Michael**

Richard & Margaret Miller Lawrence & Laureen Mori Michael Morris-Mason Julia Moss Shayne & Bailey Moulsdale Kevin & Julie Murphy The Murphy Group Nabholz Charitable Foundation Nissa & Laureine Novas Karen & Dennis O'Keefe Regan O'Leary Dylan Osmun Robert & Carol Palmer Elliott Pancio Katie Pardun Sunshine Melissa Payne Melissa & Sean Penfold Pleasant Valley Country Club Nancy Pollard The Powell Family Foundation Chelsea & Jonathan Powers Patricia & Randall Ptasznik Karen & Grant Rabon Heather & Anthony Radtke **Rags For Riches Foundation**

Rahaminov Diamonds Meera P. Rajagopalan Mark & Jacqueline Reese **Regal Foundation** Linda & Bill Richter Eddie & Elizabeth Rishty Julia Ritchie Opie & Brian Rohrer Frank & Victoria Romano Jeffrey & Paula Rosenblatt Souderton-Telford Rotary Club George & Jean Rothschild Family Foundation Jonathan & Nikole Sandoval John & Robin Scheuer Robin & John Scheuer Joe & Lucy Schneid Natalie & David Schneider Jane Schneider Martin Selleck Celeste & David Selleck Thomas & Renee Shears Jacob & Aimee Sherrick Kenneth Shigley Muriel F. Siebert Foundation Mark Silberman Khushboo Singhal David & Tara Skirzenski Perrie Smith Leane Snow Gwendalyn & Matthew Solum Mark & Lenore Spoonamore St. Joseph's Hospital and Medical Center Lauren Stearns Kim Steed Nicole & Todd Steinert Stephen & Christine Stout Ginger Swift Tague Lumber Building Material Distribution Cindy & Jeff Taylor Louis Taylor James & Mary Theobald Paul Thuriot Paul & Claudia Timko William & Jennifer Tripp Eric & Tina Marie Truhol UAMS - Winthrop P. Rockefeller Cancer Institute University Health System Marian Urman D. Michael & Claire Van Konynenburg Milan & Amit Varia

Steven & Lottie Walker Family Foundation Edna Wardlaw Charitable Trust Torrence & Brittany Warren Jennifer Watson Pam Webster Bryan & Margie Weingarten Geoff Welch Leslie & James Welter Susan Williams David & Abby Wolff Timothy & Sandy Wuliger WuXi AppTec Sales, LLC Jeremy & Katherine Zehr

FRIEND \$1,000-\$4,999

1,000.00 Bluhdorn 135 S Broadway Wine 1st Management Group **3 JE Holdings LTD** AG Foundation Michelle Abbey Abbott Laboratories Andrew Abrams Debbie & John Abrams Accessory Innovations Kelly Acevedo Linda & Scott Ackerman Christine Adams David & Susan Adams Gary Adams Atlantis Adedipe Negar & Fathieh F Adib **AES Septic** After All Carnovale Charitable Fund Selin Ahipasaoglu & Spyridon Schismenos Michael & Yifat Ahren Diane Akutagawa Sheri & Timothy Alber David Aldridge Julie & Steve Alexander R. Michael & Linda Alexander The Kevin R. Alger Charitable Fund Mahmoud Allahham Mary Delia Allen Jeffrey & Mary Dale Allen John Allen Kevin & Karen Allison Steve & Sheri Altieri Scott Altman Corey Altman **Owusu Amaning**

Peter & Marisa Amara American Asphalt Carmine & Marilyn Anania April Anderson Carrie & James Anderson Judith Anderson Ken Anderson Roger & Judy Anderson Scott & Kathryn Anderson Sarah Anderson Barbara Andreas Michael & Elyse Anitra Anonymous Anthony Anscombe Douglas & Lisa Antonacci Nicholas & Kathleen Antonaccio Jajuan Archer Arkansas Children's Hospital Paul Armstrong Cindyann & Anthony Arroyo Akemi & Keiko Arzouman Nathalie Ascencio & Julian Cano Lindsey Aschbacher-Smith Mike & Sharon Ashley **Rick Ashley** John Ashworth & Marguerite Oneto Oliver & Anita Astley AT&T Services John Atala

Melissa Atchley **ATI** Foundation Thomas Avallone Michael Avellar Robert Avery Fe Avis David Avrin Mary Lou Aylesworth Charles & Margaret Bachman Adi & Yael Badash Bernice Baeumler Stefanie Bailey & John Rurup Raymonia Viola Baugh Estate **Bailey Cavalieri LLC** Chris Baker Lisa Baker Annette Bakker & Armelle Pindon Andrea Baldwin Ashton Banks Molly Breen Bankston Barclays Bank Valerie & Leon Bare Kate Barlow Michael and Susie Barnello Charitable Fund Charles & Judy Barr The Barrel House Evelyn & Fernando Barroso Susan Barry Gabriela & Ethan Barthel

Chris Basco Anne & Ryan Base Henry & Suzanne Bass Ed & Virginia Bauersfeld Sharyn Baum **Christine Baumeister** Michael & Susan Beal James & Karen Bearns William & Janet Beaulieu Flora Beaver Derek & Tiffany Beck Jill Becker Mike & Gina Becker Christy & Nathan Bedford Daniel Beedy Tim & Jeanette Behm Susan & David Behnke Alyssa & Anthony Belch Myron & Sandra Belfer Aubrey Bell Jacob & Alyssa Bellman Deb Bement Greg & Amy Bender Ken & Mary Bender Steven & Kathy Benner Manda Bennett Alexander Bennorth Katrina Benton Eytan Benyamin & Michal Shulman Steffan Berelowitz & Meredith Lobel



Donors

Scott & Hilary Berens Dale & Jane Berg Carly Berger Berkadia Commercial Mtg. LLC Leslie Berman-Isen Maureen Berrv **Bill Berry** Ralph & Lisa Betancourt The Arun I & Asmita Bhatia Family Foundation Debra Bienert Brock Bierman James & Elizabeth Bigelow Derek Bilcik & Lynn Rooney Bilcik Graham Binder Jeffrey & Ivy Binder Melissa & Albert Bingham Brett Bingham Brooke Bissell Peter & Maurine Bisson Jake & Becky Bjorklund Dan & Lynne Black Black Rock Foundation Fund/Donald C. McGraw Foundation Blair Academy Karen Blakelv Kevin & Denise Blakeslee David Bland & Susan Lesh Chris Blechschmidt Dennis Block Emma Bloomberg Blue River Wood Products Blue Sky Birds **BMW** Championship Volunteering Jessica & John Bodel Boehringer Ingelheim Austria Elizabeth Bogardus Christopher Boling & Carla Seibert-Boling Brenda Bolt Brett Bolton Peter & Danielle Bonadies Anthony Bonadies Michael Bonevento Nelson & Carolyn Bonheim Jacquelyn Borgmann Amv & Kevin Boulas Andrew Boyd Miles & Melissa Boyer Erinn Boyle Al & Ann Brabant Franklin Brady Patrick Brady

Romulo Braga Sandra & Jonathan Bragaglia Jon & Lindsay Brager Katl Brand Lora & Christopher Brann Matthew Brasher Don & Tina Brauning Joseph Breton Brewer Family Gift Fund Bridlewood Midwest Insurance Charles & Elizabeth Brinklev Jack & Sharon Brinnier Bonnie Broan Linda Brodsky Ronda Brodsky Vickie Brookings Rebecca & Rebecca Brooks Janet & Rick Brown Rebecca Brown Shirley Brown Thomas & Dorothy Brown Andrew & Elizabeth Bruce Jason & Christina Bruegger William & Nora Bruemmer Lesley Brunstetter Sara & William Bryan Cary Buchman Brian Budnick Bernie & Mary Beth Buescher Sally Bufton Clark Bugg Josh & Megan Bugle Edward Burdett James & Marv Burdick Susan Burke Gael Burman Mark Burnham Timothy & Andrea Bushaw Susan Bushman Melissa & Danny Busler Katherine Butler Jonathan Butwin C R Fuel Joel Cadman Alison Campana Ann Campbell Thomas Campfield Maria Campilonga Canon Solutions America Renee & Robert Capano Joseph Caracci & Barbi Lee Lynsey & Austin Carithers Alan & Clare Carlsen Michelle & John Carlson Kelly Carmon Jaimie Carol Woods Nancy Carver

Catherine Christie

Phyllis Chung

Kryssy Ciarlo

Association

Jason Clairmont

Virginia Claar

Aaron Clark

Christie Clark

Scott Clasen

Anne Cleary

Thomas Cleary

Nadezda Chupak

Zachary Christinson

Church & Dwight Co., Inc.

Cincinnati Food Truck

FIGHTER. NF SUMMI WWW.CTF.ORG Courtney Cashman Tracy Clere Erasmo Casiano Melanie Cleveland Cynthia Cassandro Maegan Cobb Jerry Casselano Rodney Cobos Sandra Casselano Lisa & Leo Cocanougher Christa Castanon Tiger Coffman Jennie Caven Cohen Cleary, P.C. Elizabeth Celauro Jonathan Coker Darci Celey Seth & Jody Colaw Sajiv & Elesha Chandradas Kimberly Cole Dale & Howard Chapman William & Suzanne Coleman Andrew Chatburn Joann Coleman Mark & Sharon Chertok Coleman, Chambers & Katie & Nicholas Chiaratti Rogers, LLP Raymond & Anna Chin Colfax Marathon Partnership Alison Choate Colgate-Palmolive Company Jenny Chou Silverio & Kathy Collins Brian Silverio **Collins Management** Rodney & Mercedes Christesen Foundation

Sylvia & Miguel Colon

Brigham G. Colton

Rachel Cone-Gorham

Ross & Christine Contiliano

Compass Inc.

Hudson Cone

Lauren Conner

Sara Connor

Andrea Cook

Gordon Cookson

Peter & Julie Cooper

James Cooper

Jim Cooper

Sandi Cooper

Colonial Wines and Spirits

Jim & Terry Corcoran Lori & Alex Corona Michael Corssen Daniel Cote Tommy & Elisa Coulter Matthew & Gwendolyn Coverdale Jason & Faye Cradit Porter & Kori Crawford Deal Paolina & Timothy Crouch Jonathan Crowe Robert & Susi Cruz Jerry & Lorie Cudzil **Deb Cummings** Charles Cunningham Reed Cupps Julie Currid Brian Cutler Brian D'Anna Richard & Carolyn Dahab Larry Daigle Tina Damiano Peter Dandini Kristina Dandurand Sequoyah Daniel & Carole Mitchell Maura & Richard Daniels Chelsea Daniels & Evan Walbridge Clifford & Kathryn Daugherty Lynn & Michael Daugherty Dee Dee Daus Diego Dayan Moshe & Pamela Dayanim



Paul De Blank Matthew & Meghan DeAngelis Robert & Stacey DeCillis William Decker Amanda & Justin DeFreece Adam & Alissa Deitz Janisse & Alejandro Delestre Sydney DeMarco Mari Wiseman Deminski Brad & Linda Demsey Tad Dennis Design Continuum Becki & Shawon Deuel Matthew DeVinney **DeVinney Family Fund** Brett Devriendt T. Michael & Dianne DeWitt Jim Dewulf Nirmala Dharmaraja Milagros Diaz Otto Dick Craig Dickman & **Elizabeth Engels** Valerie & Taylor Didonato Sandy & Todd Dietrich David Dietz John & Patricia DiNozzi Barbara & Tony DiSario Disneyland **District Council 16 DLP Unlimited** Kevin Doane Jason Doele Jessica & Pat Dolan Charles Dolish Darin Donahue Bob & Lynne Donohoe Emily Donovan David Dosberg Gail Doughton Laura Douglas Joseph Downey John & Julia Doxsie Aleksandra Drebskava & Amaro Velasquez Kevin & Silvia Dretzka Vincent & Juliet Driscoll John Duder & Anne Mele Maria & Michael Dugan Maxwell Dugan Michael Dugan Phil Dunkelberger Brenda Duno Al & Mary Duvel Hudson Eastman David & Gayle Ebel

Lindsey Ebert William Fbert Mike Eden Max & Pam Edwards Caroline Egrie Ogochukwu Ekwuabu Frederick Elder Rav Ellin Michael & Jill Elliott Peter & Carla Emanuel Robert & Denise Emolo Empower Retirement LLC Entergy Arkansas, Inc. Doris Engel Ryan Engelmann **Christopher Enger** Larry & Marilyn Ennis Michael & Kori Enslev **Enterprise Holdings** Foundation Travis Ernst Lottie & Alfonso Esteban Robin Esterkin Brandie & Brett Evans Jason Evans Kristy & Christopher Evans Steven Exceen Extravega Joe & Jodi Fadool James Fagan Michael & Laura Faino Lisa & Neil Falcone Robert & Megan Fante Shannon Farrer Sara Fast Emme Fawcett Pamela Feick Peter Feinberg Joseph & Sherry Feldpausch Geraldine Felicia Linda Fergus Isabella Fernandez Luisa & Brian Ferruggiari Festivals Unlimited Sean & Jill Fettes Todd Fink Rose Fiscella & John Novello Joseph Fischer FJC Brent & LaNece Flamm Robert & Cynthia Fleming **Kimberley Flickner** Laura Florio-Ellis Nicole & Dan Flowers Andrea Foltz Jackson Fong The Ford Family Foundation

Jean & Kaylee Forde Michael Fordosi Joanne Fournier Franco Manufacturing Stephanie Franco Daniel & Norma Frank Melissa Frank Barbara & Michael Franklin Hayden & Lynne Franks Heather Frazier Bonita Frazier & Jacqui Brebnor Freebeat James I. Freeman Charitable Trust Freeze CMI Anne Friedman R David Fritz Alexandra Fruin Carly Fulbright W.J. & Cecelia Furlong Jennifer Furr Jeffrev Gabler Robert & Jean Gabler Ginger & Jay Gahr George & Lara Gaine Adrian Galaz Christine & Erick Gallager Doris Gallowav Shawn Gammell Nicholas & Mary Jane Ganas Thomas & Rosemary Gangel Angela Garbarino-Buffkin Teresa & Russ Gardner John Garr II G. Lee & Chesley Garrett Edith Garrett Todd Garten Louis & Judy Gautreau Julie & Davin Gebauer Liz & Rick Gebhardt Grace Gede Janete Geller Mauro Geller Jerilvn Gelt Marsha Gelt Jennifer Gentile Benson & Rick Benson Jamie & Alison George John Geracitano Hans & Phyllis Geres Margery Gering Feinberg Jobie Germano Glen Geurin Levla Ghassemi William Gholston Fred & Karen Giardinelli

Danielle Gibbens Jeffrey & Meredith Gibbons Kenny Gibbs Lindsey & Jeremy Gibson Bryan Giesecke & Amy Frakowski-Giesecke Laura Gildersleeve Merrill Gildersleeve & Anore Novak Michelle Gill Sean Gillespie Gilliardi Logging Tamara Gineo Ronald & Toby Gish Bernard & Brenda Gitlin Daniel & Kristen Glazer Philip Glynn Jaclyn Godic & Bradley Reynolds Andrew Goffe William Golden Steve Gombach Arthur & Carol Goodman Enrique Goodrich Nikki Gordon Nikki Gore Christine Gorman Randy & Jeri Gort

Lauren Gottlieb-Mora & Fernando Mora Grand Council of Cryptic Masons of the State of New York Grande Maumelle Sailing Club James & Pamela Grange Ronnette Grant Patrick & Eileen Grasso Zach Gratton Andrew & Hallie Gravelsins Darlene Grav Candice Graytok Seth Greenwald Heather Gregorio Holly Griffin Kalene & John Griffith Steve & Vivian Griffith **Richard Grigsby** Joseph Grippe Charles Groeschell Veronica Gromada Ouattlebaum, Grooms & Tull PLLC Howard & Marcy Gross Luray Gross & Paul Koehler Renee & Martin Gross



Donors

Susan Grunfest Daniel Guaglianone Carrie & Gregory Guillory Chris & Anne Gumino Shalini Gupta Alice Gusherowski Carie Guyah Hillel & Ruth Hachlili David & Trudy Hackett Hackett Family Foundation Lawrence & Shannon Hadley John Haener Trent & Marianne Hagiya Kellie Hale Robyn Hall David & Gina Halme Bat Sheva Halpern Victoria Hamilton Dawn Hamilton-Riddick Margaret Hamor David Handy Kevin Hanlev Michael & Pamela Hanley Katie & Timmy Hansley Hart & Brigitte Hanson Jeff Hanson Fund Jon & Sharon Hanzel Sandrine Hardouin Julia Harmatz John & Janet Harper Steven & Jeanette Harper Karin Harrington Nancy Harris Marc Harrison Brandi & Aaron Hauser Lindsey Hawes Michael Hawkins Jason & Meredith Hayes Richard & Joelle Heald Monique Hebert-Bublyk & Nicholas Bublyk Robert & Aysel Heckel Alexander Heckler Anna Hedlund Gene & Judith Hendrick Ashley & Bryan Hedtke Sharon Heflin Melissa Heggen Susan Heil Elizabeth & Gordon Heil Layne & Lynn Hellickson The Helis Foundation Mathew Helman Robert Hendrickson Jason & Anna Herd Rebecca Hergert

Jacqueline Hernandez John Hernandez Gioia Hernandez Family Fund Katherine Herold Maurice Herz Mark Hewines Susan & Herren Hickingbotham & Hickingbotham Investments Barbara Hicks James & Virginia Higgins Darby Hill David Hill Elaine Hill Alice & Tony Hillbruner Hirshleifers Brandon & Amanda Hitt Terry & Patty Hobson **Denise Hodes** L. Lee & Carole Hodges Elizabeth & Kester Hodgson leff Hoen William Hoffman John & Michele Hogan Thomas & Andrea Hogg Michael Holcomb Allan & June Smith Holladay Lisa Hopes Peter & Dana Hopper Marie Horner **Brian Hoskins** The House of LaRose Nichole & Kabir Houston John Howell lane Howland Jason & Heather Hudson Eric Huebner **Brad Hughes** Brandon Hull & Paige McDonald Hull Betina Hunt Greg Hunteman Brian Hupfold Denise Hurley Elizabeth Hurley Michael & Donna Hussey Asa & Susan Hutchinson Budd & Katelyn Hutchinson Steven & Kimberly Hutchison Mark & LaDeana Huyler David & Jan Ichel John & Jessica Illuzzi ImpactAssets Laurie Ingerman International Union of **Operating Engineers Local 12**



Intex Recreation Corp Intuit Foundation Margaret Ippolito Robert & Patty Isen & Family Sondra Isen Jackie & Jim Iversen Carmen & Shannon Jacobson Karen James W. Thomas & Deborah lames Krishna Jammula Laura & Fred Jaramillo John & Sally Jarboe Jean Bates & Associates Timothy & Walda Jefferson Jefferson Regional Medical Center Jessica & Salvador Jemente John & Grace Jenchura Mary Ann Jennings Jav Jensen Christina & Jeremy Jewart Jewels By Park Lane, Inc. Jay Jinks Maria Joffrion Andrea Johnson Carlos Johnson Frik Johnson Maria & Mitchell Johnson **Timothy Johnson** Kelsey & Trent Jones Nicole & Shane Jones Noah lones Shirley & Ted Jones Sissy & Murphy Jones Joann Joy Laura & Kiran ludd Kenneth & Dorothy Juell Michael & Gay Julian

Judevine Chiropractic & **Rehabilitation Clinic** E. John & Nancy Justiniano Julie Kaehler Robert Kahn Robert Kane Kenneth & Judy Kaplan Beth Kaplan Nina Kaplan & G. Minot Clements Anastasia Katinas Aubrey & Roleen Katz Derek Kaufman Burcharanjeet & Gurcharanjeet Kaur Lesley & Jonathan Kaye Harry & Carolyn Keagler Phil Kearney & Jess Earle David & Rikki Keating Jim Keet Keet O'Gary Construction Colin Keller Elisabeth Keller & Steven Bonsey Kate Kelley Allen & Vickie Kelley The Kelly Sherwood Family Charitable Fund David Kellv Erin Kelly Kristina & Ian Kelly Marcus Kelly Harris and Eliza Kempner Fund Joe Kemphaus Kendra Scott LLC Richard & Nancy Keshian Daren & Emily Kest Bryan Kest

Bob & Judy Kesterson Jennifer & Kevin Kibler Patricia Kidd Debbie Kiefer Lauree Kielv Elaine & Jeremy Kilpatrick Jennifer Kim **Dianne King & Francis** Murphy Nicola King Bradley Kinley Risa Kirsh Christina Kist Elaine & Stephen Kist Kitsap Chico Towing Kiwanis Club of Midlothian -Chesterfield Diana & Michael Klages Ronni & Michael Klein Abram & Debbie Klein Laura Klesse George & Joyce Klett Kevin & Geoconda Arguello Kline Lawrence Bowen & Lisa Knaust Brooke Knutzen Katie Kobzeff Lauren & Tucker Koch Sean Koelbl Bruce Koepfgen George & Jutta Kohn Michelle & Jason Kolb Dana Kolderup Lara Kometz John & Jacqueline Konechne Christopher Korherr Lance & Aly Kotal

James Kraft & Kristine Nystrom Susan & Alex Kreher Laura Krietemeyer Jeff & Michelle Kroll Deborah Krulewitch Daniel Krzeminski James & Patricia Kuchta Nicole & Mike Kunkel Stanley Kwiecien Melissa & Scott LaBean Albert & Ursula LaBrusciano Cindy Lai Matt & Tracy Laird Phillip Lakin Robert & Maureen Lamb Kyle Lamb Michael Lambert Patrick & Fran Lampman Megan Lampman & Kyle Champley Catherine Landman David Largaespada Lindsay & Christopher Larsen Catherine Laskey & Mark Ebel William Lauder Valarie & Brian Laverack Justin & Ellen Lavinsky Gary Lawhon Keith & Lisa Layton Raul Lazaro lule Katrina & Michael Leach Chandler & Alyssa Leathers LeChase MaryJane LeCroy John & Edyth Ledbetter David Ledbetter Doreen Leddy Frank Ledezma lennifer l ee Thomas Lee & Maria Biasotti Lee Legacy Termite's Pest Control, Inc. lassi Lekach Deborah & Dewayne Leming Len Camber Charitable Trust Thomas & Brienne Lenart Richard Lennox Robert & Kim Leonard Seymour & Barbara Leslie Foundation Margot & Larry Lessans Greg & Nadia Letey David & Erin Levesque Matthew & Stacy Levy

Raymond Lewis Annamarie Lichiello LIFEwest Northern California Ambulance John & Kate Ligon John Ligon Limestone Veterinary Hospital Magnus & Marketta Lindeback Stacev Lingo Paul Lioce Paul & Yael Lipof Jack & Meghan Liston Xuxu Liu Thomas & Amy Loeffler Ethan Loftspring Sharon & Peter Loftspring Zack Loggins Pamela Lombana Beverly & Tyler Lorig Rebecca & Tripp Love Alan Lovegreen & Rory Moore Dawn & Andrew Lowell Christine Lucas Nick Luchsinger Melissa Luciano Chris Ludemann-Davis Justin Lujan & Rachel Anderson Lul aRoe Inc. Patricia & Steven Lund Lyall Family Charitable Fund Fernanda Lynch James M. Lyons Doug MacCallum & Shannon Simmons Didi MacDonald Tyler & Alicia MacDonald Lisa Mackey Tina & Jeff Mackie Stephanie Maclennan William C Magill Katie Maguire Jack & Diane Malarik Traci Malek Frederick & Stacey Maler Andrew Malin Daneen Malloy & Erica O'Gradv Patrick & Hilda Malone Melanie Manchester Bruce Mandell & Lillian Garcia Michael & Shannon Manfredo Ursula Manganaro Jonathan & Dawn Mangum

Karthikeyan Manickavasagan & Selvi Ramalingam Patricia Manjorin Erin & Jared Mann Crista & Levi Mann Eric & Betty Mannes Kelly & Seth Manning Guy Manuel & Linda Goldstein Doreen & Louis Marangoni Jenny & Kyle Marik Christal Marincic Ionathan Mark Luke Markes Zachy Marks Alison Marooney Patrick Marsch Edith & Christopher Marson The Martin Andersen-Gracia Andersen Foundation, Inc. Fiona Martin Kevin Martin Sue & Gary Martin Todd Martin John Marty Lon Mason Lindsay Mastry Emma Matheson Bradlev & Katherine Matthews Breanna Matylewicz Krista & Benjamin Maxwell Mavo Clinic David & Beth McAlexander McCain Foods USA John & Loren McCarthy Michael & Kim McClincy Will McClung Daniel & Jennifer McConnell Sandra L. McCorrv Chloe Mccoy Duane McCurdv Brooke & Pat McDonald Lisa McFarland Monica McGill McGriff Insurance Services Jacqueline & Jacqueline McGuire Carly Mckay Luke McKeen Meghan McKeon & Paul Hunt Roseann & Bradley McKeown Shawn & Erin McLevige David Mclure Allison & James McMeechan Jason McMeen Katie McMenamin Tim & Michele McMillin

Caitlin & Kane Mcmurray Shannon & Walter McNall MCO Cartage, Inc. Latasha & Steven Mcpherson Jessica Meadows Jon Meek Marilea & Nordolyn Meguiar Josh & Dawn Meier Paul & Lili Meilink Linda Melada & Arthur Levine Zach Mellen Clayton Mellina Antonio & Ruth Mello Memorial Hermann Andrew & Dawn Merrill Kellv & Karl Mertz Aaron Metrikin Kimberly Metzger Paul & Deborah Michael Jeffrev Michaels Ann Middling Larry & Amy Midlarsky Fernando & Ana Mijares John & June Miley Clyde & Marcia Miller Sean & Julie Miller Charlie Mills Thomas & Janice Milone Alex & Jody Mincks Wendy Mines & Eleanor Sue

Ashley Miskowski Marshall Mizrahi Sara & Ralph Mizraji The Moelis Family Fund Steve Moglia Jessica Mohideen Hank & Christy Mohr Sandra & Robert Moler Linda Molinari Jason Molluso Katherine & Stephen Montgomery Scott Moore Briana Moore Lauren Moranz Stacey Morgan James & Elizabeth Lee Morgan **Thomas Morrell** Glenn Morrison Jess & Joe Morrow Jay Moss Dan & Anja Moss Dan and Anja Moss Charitable Fund Raymond Mott N.K. & Donarae Moulsdale Gary & Rachelle Moulsdale Eric & Michele Moyer Mr. Big Shots, Inc. Patrick Mullins Joanne Mullins



Donors

Jeff & Sherry Muniz Mayra Munoz & Luis Duran Munson Chiropractic, PA Audra Murphy Brittin Murphy Kevin Murphy Rebecca Murphy Tara Murphy William & Karin Murphy Ted Muzika Kelly Myers Patricia Mylander Ramanathan & Sakunthala Nagappan Carly Nance George Nanos Amy & Sam Napier Nat and Marcia Sterling Charitable Fund National Fuel Gas Company Foundation Neighborhood Dental Tara & Scott Nelson Josolvn Nelson Dan Nestor NewGen Strategies & Solutions, LLC Leah Newell Meighan Newhouse NFL Foundation P. Leia Nghiemphu Pam Nicholson Elisabeth & Hans Nilsson Stephen & Anne Noble Becky & Cary Nobles Kathleen Noe Matthew Nordin Alan Nordstrom Neal Norman Michael Norris & Kirsta Scherff-Norris Jim & Paula North North Georgia Community Foundation, Inc. Northrop Grumman Corporation Alexandra Norton Boris & Marcia Novak Kathrvn Novaria Therron & Pamela Nowlin Robert & Christine Nuernberg NuStar Foundation Anna Nyman Diane Marie O'Malley Judith O'Neill Mike & Mary Kay O'Rourke Michael O'Rourke

Kevin & Susan O'Shea Chervl & Bob Oakes Tamela Oakley George & Patricia Obst John Odom Andrew & Wendi Offsev R. Wayne & Emily Ogozaly Ogozaly Charitable Fund Sam & Young Sook Oh John & Heidi O'Hare **Richard & Caroline Olgee** Michael Olivere Ashley & Elliott Olson Lauren O'Malley David & Patti Ongman Simon & Dana Oren Ivan Orlic JoAnna Orozco Anne Mary & Chad Orr Christi Osborne Ian & Shannon Osorio Darcy Osorio Caitlin & Theo Ottesen Thomas & Mary Ann Oven Scott & Jody Overcarsh Stephen Owens Shoheen & Theresa Owhady Larry & Karen Oxman **Oyster Bay Lions Club** Foundation Bob & Karen Packard Manuel Pagaling The Pampered Chef Kaitlin & Timothy Pancio Richard & Joni Pankow Pauline Panza Nicholas Panza Par Plumbing Co. Esther Silver Parker Francine Parnes PASCO Allie Pasquale Saral & Bina Patel The Patrick Michael Rubin Scholarship Fund, Inc. Cheryl Patton Malloy & Joseph Malloy Susan & Joe Pavlisko Brian & Sarah Payne Marion Pearlman Melissa Pecoy-Jungjareon Peter & Vicki Pellerito Todd & Beth Penney Mark Percival Alfonso & Doris Perez Lauren Perovich Douglas & Colleen Perry



David & Marlene Persky Michael & Shelley Pesta Alison & Jeff Petersen Amanda Petrak Erica Petras Sonya & Lance Petree Lien Pham Philadelphia Phillies **Christopher Philip Beth Phillips** Kenneth & Stephanie Phillips Phoenix Children's Hospital Brian & Mary Picarello John Piccinini **Thomas Pierce** Jennifer & Chris Pierson Frank & Margaret Piil Zach & Michelle Piner Mendel Pinson Kate Pisani Charles & Patricia Pittman **Emily Pittman** Erin Pitts PKF O'Connor Davies Pleasant Valley School District -Student Activity Fund Judy Pollack Brook & Jamie Polling Marilyn Polson Brad Polzar C. Lorraine & Andrew Pompo Robert & Nicole Pompo Poppy Bank Karen Porter **Christopher Powala** Victoria Powell Randy Powers Cory & Michael Powl Margaret & Mike Powl Practical Products Co. Martha & John Pregler

Debra Pregler Prestige Consumer Healthcare Ronald & Patty Price William Price & Linda McWey Price Edith Procopio **Prospect Studio** Michele Przypyszny Cathy Puleo Michelle Pulkrab John & Sherry Pulsinelli Tina Pun **Quality Technology Services** Charles & Margaret Quilty Howard & Mara Rachlin Robbin Rahman Eric & Patricia Ramstrom Mary Randow David Levi & Nancy Ranney-Levi Amy Rapawy Melissa & Michael Rasco **Rathgeber Family Foundation** Peter & Michele Raymond Michelleta Razon Kurt Read The Dale L. Reese Foundation Anthony & Regina Realmuto David Reciniello Daniel & Lisa Reck Bernard Rehill Kevin Reid Daniel & Joan Reilly Marguerite Reilly **Relvance Bank** Mary A & Scott Revolinski Adele & Robyn Rhinehart Elizabeth & Walker Rhoda Melvin & Patricia Rice Brandon & April Rice Randall & Debra Rich

Nicole Rich Mary Ellen Richards Mark & Tina Richey Brian & Melanie Rickmann Joseph & Lynn Ridder **Kimberly Rieders** Lauren & Dave Rigby **Rigney Plumbing** Jennie & Eliott Rimon Charles & Donna Riser John Risner & Sharon Parente Michael Ritche Michael Ritchie Zoe Rivera Ozem Rivera Bryan Robbins Anthony Roberson Lauren & Donald Roberts Albert A. Robin Family Foundation John Robinson Kimberley & Brian Robinson Reva Robinson Richard & Becky Robinson Jenna Robles Sheryl & Gregory Roche Cheryl Rocheford **David Rodgers** David L Roeder Rosaly Roffman Terence Rogers **Dirksen Rogers** J. Thomas Roland, Jr. Scott Ronayne Chris & Kelly Roper Amanda & Michael Rose John Rosen James R. Rosenbloom James & Cheryl Rosenthal Harold & Anita Rosnick

Toni Ross Tena Rosser & Raz Schionning Fern & Steve Rotfeld Ronald & Carol Rothrock Ronald & Ursula Rottloff Ashley Rowe Debra & Louis Rowe Mike & Janine Rubendall Allan Rubenstein & Jane Halperin Judith & Dan Rubert Ronald Rubin Arik & Naomi Ruchim Cheryl Rush Patrick & Denise Russell Theresa Russell Ed Ryan Marcia Ryan & Neil Farrow Daniel Ryave Michael Saidi Salem Presbyterian Church Robert & Nancy Salka Susan Salpeter Salter Construction Inc Peter & Christina Samaras Mark & Donna Samblanet Shawn & Tracey Samuels Bennett Sands Kara Santacroce Stephanie & Jonathan Santin Melissa & Christopher Santos Saracen Casino Resort Alyssa & Nikko Sarno Carol Sassa Faith Satterthwaite Shannon & Alexander Savage Elizabeth Sawicki Jacqueline & Thomas Sax Natasha & Tim Saylor Leanna Scaglione Douglas & Nancy Schaefer Andrew & Amy Schafer Robert Schafer & Jean Pavone-Schafer Julie Schaller-Schmidt & John Schmidt Jason & Machelle Schallhorn Valerie Scheder Michael Scherl Lauren Schiller Teresa Schirmer James & Andrea Schloemer Schlueter-Valentine Charitable Fund Jessica Schmidt

Scott & Tricia Schmunk Linda & Jonathan Schulman Marshall Schuster Rich & Holly Schwarck Mark Schwarzgorn Mary Scianna Donna & Matthew Scotty Carrie Scully Eleanor Seaman Seattle Children's Hospital SEI Investments Francesco Semeraro & Pasqua Laghezza Carole Servidio Keith & Piper Severns Brian Seymour & Amy Maddaluna Seymour Shape Process Automation Sharon Duerr Real Estate, Inc Kitt & Ronald Shaw Richard Shaw & Katherine Watkins Joe Sheehan Richard & Ilene Levy Sheng Lori & Chad Sherman Shewmake Plastic Surgery Yehuda Shmidman Ali Shoja Nick & Linda Shores Laura Shudrowitz Jack Shurbet Amanda Siecinski Jordan Siegel Signature Bank of Arkansas Wendy & Robert Silaghi Jeffrey & Francine Silesky Silicon Valley Bank Rich & Kyleen Silvas Mike Silvestrl Tim Simmons Laura Sinacori Kevin Singh Sahil Singh Steve & Laura Sink Joel Sirianni Don & Nancy Skaff Michael Skiber Randall Skinner Adam Slackman David & Laurie Slackman Rolly L. Slatt Melinda Slatt-Friedeberg & Daniel Friedeberg Todd Slaughter Sluggers Inc Alan & Diana Smagler

Amy & Pat Smith Dennis Smith Jessica & Derek Smith Gena Smith Katie & Caleb Smith Courtney Smith Lisa & Timothy Smith Natalie & Stephen Smith Robbie Smith Stanley & Penelope Smith Taylor Smith Smokey Mountain Chew, Inc. Gregory Smolinski & **Christine Matthews** Smylies, LLC Kimberly Snipes Adam Snodgrass Rob & Rachel Snyder Lee Soares Robert & Nina Sobel Daniele Sobrini Fazel Solomon Grant Somerman Ernest & Doris Soriano Doug & Riley Soulliere Kathleen Sousa Thomas & Linda Sparks Juanita Spears Spielman/Baumgarten Family Fund Andrew Springer Drew & Casey Squires **Richard Stacey** Todd & Janice Stahl **Kimberly Stallings** Tracy Stamer Randall & Shabnam Stanicky Christopher Stanley **Chelsie Staples** Edward Starishevsky Steamroller Blues Little Rock Lauren & Jacob Stearns Aaron Stebner The Stecher Family Fund Walter & Priscilla Steenbergen David & Rachel Steerman Rachel & Freddie Steerzer Mark Philips & Sylvia Stein **Rachel Steinberg** Carol & Witt Stephens Charitable Foundation Janet Sterling Ed Stern Cynthia A Stevenson Matthew Stevenson Stifel

Gary & Estelle Stinchcomb Larry & Mary Kay Stoor Leanne Story Martin & Alesa Story Melissa Stott Hanna & James Straw **Billie Sudbrack** Suffolk Transportation Service, Inc. Joseph & Barbara Sullivan Robert Sullivan Marlee Sumbrum Michelle Suna Aaron & Mariorie Suna Zoe Match Suna Seouri & Ethan Sung Ann Svoboda Debra & Ray Swafford Clifford & Kay Sweet John & Michelle Sweet Annabelle Swift David Shane Swift Susan Swift Dyan & Jory Swim SYSCO Food Services of Central Florida Stephen & Priscilla Szachacz Julia & Ralph Szulerowski Adam Taitz

Jenna Takes

Jeffrey & Jacki Talbot Tall Oaks Creative Lee & Debra Tannenbaum Michael Tapley Laurence & Pamela Tarica Paige Tatulli Andrew Taucher Cindy Taylor Miranda & Brett Taylor Rebecca Taylor **Teleflex Foundation** Doris Texter Erin & Bay Thammavongsa Katy Thayer James & Caroline Theus William & Susan Thomas Christopher & Nancy Thompson Donald Thompson John Thompson Todd Thompson Annelise Thomsen Brock Thornton Mark & Tifanee Threadgill L W Thynge Tom Tilaro Farida & Satrohan Timal Donna & David Tipton Thomas & Lauren Tobin Alex Toccin



Donors

Priscilla Tollin Alexander Tolpin Ethan Tolpin Jonathan & Tracy Tolpin Leslie & Donald Tomeny Arthur Tonelli Total Tire & Automotive Debbie Tranter Robert & Jeannine Tribuiani Clare Trollo Joseph Trollo **Richard Tropiano** H. Trotter Trotter Foundation James Trudeau Stephanie Trudeau Larry Trussell Karen & Nicholas Tseffos Steve & Kathy Tucker David Tuma Sarah Turner Charlie & Terri Turner Sarah & Robbie Turner Tyson Foods Joseph Umdenstock & Elana Wills-Umdenstock University Of California, Los Angeles **Greg Unterbrink** Wayne & Mary Ann Upshaw Karen Ursic UW Medicine Daniel & Becky Vacanti Catherine Valcourt-Pearce Gina Valentine & Paul Schlueter

Angela Vallot & James Basker Michael & Carole Van de Kerckhove Robert & Cathy Van Gilder Mark Beave & Laurie Van Metre Brian & Rachael Van Ness Jo Ellen & Myron Vanatta Chris & Kelly Vanavermaete Patti Vance Lydia Vanderloo Weba Allan Vanderplaeg Dawne Vandiver Cameron & Gregory Vanore Stephen & Christine Velott Stacy & John Verdi Nicole & Leonardo Vernacchio Ronald & Lori Vernier Laura & Attila Vertes Candie & Shane Vicars Henr & Daniel Vincent Dave & Barbara Viskochil Vogel Schwartz Foundation Margaret & Daniel Voissem Simon Vukelj W.Y. Campbell Family Foundation Robin & Philip Wachtler Sabrina Wagner Nick & Melissa Wahal Jane Wainwright Kimberly & Paul Walker Scott Walker Elizabeth Walklate Joel Wallace Tyler Wallace

Tony Waller Harold & Laura Wallof Kasev Walls Richard & Carol Walsh leanette Walter Andrew Walton McKenna Wangen Carol Ward Stone Ward Timothy Ward Derek Warden & Margaret Laudise Ware Family **Richard Warren** Jennifer Warzecha Thomas & Ruby Wasden Joan Waters R. Jim & Mary Ann Watts The Wawa Foundation, Inc. Dane & Mary Ways Patricia & Jeffrey Weaver Ronald & Christine Weese Katherine Weigartz Theresa Weigartz Josh Wein Kara Weingartz Alan Weinstein Pete & Katie Weir Sabrena & Wayne Weisenburger Julie Weiser Howard & Donna Weiss D Bradley Welling Benjamin Wells Roger Welsh Dennis & Susan Wennerberg Amanda Wesenberg Susan & Randy West Allan & Michele Westervelt Kenneth & Christina Westnedge Maura Whelan Keegan & Joanne White Larry White C. Richard Whitson Michael Whyte Aaron Wickersham Angela Wiesmore & William Mack Alejandrina Wiggins Ian Wildman Mark and Jane Wilf Family Foundation Aaron & Jenni Wilkerson Andv Wilkes Keith William Dan & Ellen Williams Greg & Doris Williams Teresa & Kevin Williams John Williamson Stuart Wilms Daniel Wilpon Andrea & Jeremy Wilson Dawn Wilson Kathy Wilson Lavton & Ann Wilson Matthew Wilson Terri Wilson Cheryl Wilton Alene & Cart Wintroub Barry Wiseman Deanna & Kurt Wisthuff

Barbara Witcher Justin Witt Daniel Woerner Natalie & David Wolf Natalie Wolf Pamela Wolters Wonderful Giving Melissa Wood Nicholas & Carrie Woods Rvan & Maria Woods Walter & Patricia Wozniak Jason & Charity Wratchford Daniel & Suzanne Wren Megan Wright Margaret Wright Julie Wynn Janice Wziontko Betty Yaeger Mark Yaquinto Bonnie Yeager Suzanne Yee Yottaa Inc Patrick Young Ken & Jessie Yue Amy Zabel-Nordstrom Samuel & Elizabeth Zanontian Thomas & Amy Zeifang Sabina Zetrenne Bill & Nancy Zisson Bart & Tracy Zitnitsky Petra Zorn Nancy & Gerard Zuch John Zurliene

CTF Board Alumni

Christer Agell* Peter Aron* Lee Babiss* Peter Bellerman **Robert Bernat** Louis Berra Laura Bona Amy Boulas **Bill Brooks** Colin Bryar John Catsimatidis Joel Cohen Lou Congelio Lynne Courtemanche Shapiro Marian Crisci David Cross

Paula Dickerson Madelyn Donoff Suzanne Earle Mark Ebel Maria Escandon Kennetha **Esters-Strange** Leslie Ann Fox **Patricia Francy** Aram Fuchs Jake Garn **Dolores Goldfinger Daniel Graeff** Anita Gribben James Gusella Brendan Hanrahan Susan Harvey

Matt Hay **Kimberly Higgins** Mays Joel Hirschtritt **Kim Hunter** Catherine Jaeger **Richard Jaffa** Jesse Jenner **Bruce Judson** Alfred Kahn Michael Katz Ben Kohnle Antoinette Konski Bruce Korf **Kirstin Kurlander** Joan Kushner Chad Leathers

Marshall Loeb **Stephanie Longtin** Michael Lucas Jill Markland **Rosemary Marks** Durant John McCarthy Juli Middlekauff Dee Milligan Doretta Milligan Mark Moonev Renie Moss Michie O'Day Lesley Oslica Joanne Pastel Laura Perfetti Michael Peterson

Denise Pitzman Jason Pontin Jane Pugh Jessica Quintana Harold Ramis* John Risner Alan Robbins Allan Rubenstein Robert Schaffer Doris Schnuck **Bernd Seizinger Carolyn Setlow** Kyle Shannon Colby Shapleigh Tara Skirzenski Mary Lou Smith **Connie Sorman**

Edward Spiegel Yvette Spirito Susan Stewart William Tarbart Karl Thomson Rachel Tiven Lisa Trygg Steven Utley Dave Viskochil Nate Walker Margaret Wallace Sally Wallner Farah Walters Bonnie Young

*Denotes deceased



NF Legacy Society

As a supporter and friend of the Children's Tumor Foundation, you have been vital in building us up from a grassroots group with just a few members into the leading organization we are today, fully committed to finding treatments for neurofibromatosis. Make no mistake about it — the progress that has been made in the fight against NF is because of people like you, who are working to improve the lives of those with NF. It is a legacy of which you can be proud.

Our vision is to end NF. We owe it to future generations of NF patients and families to see that vision become a reality. And as long as there is the Children's Tumor Foundation, there will always be an advocate fighting hard for the NF community. By making a special legacy gift to the Children's Tumor Foundation, you will play an important role in ensuring that this work continues. Your planned gift is an investment in the long-term future of the organization, ensuring that the Children's Tumor Foundation will continue to lead the way in the fight to end NF.

The Children's Tumor Foundation NF Legacy Society consists of individuals who have taken the extra initiative to ensure the future of NF research by including the Children's Tumor Foundation in their estate plans.

To learn more about leaving a legacy and making a planned gift, please visit freewill.com/CTF, contact the Foundation at info@ctf.org, or call us directly at 1-800-323-7938. **Donors:** NF LEGACY SOCIETY

Patricia Bacon **Eileen Wynne Ball** Michael & Lindsey Barnett Anna Barrese J. Michael & Joy Blankenship Christopher & Jessica Bragg Robert Brainin & Nicola Kean Angela Buffkin Gene Casciari, Sr. **Geoffrev Cohen** Jeffrey & Wendy Dankey Robert DeVinney Bonnie Eisenklam David & Sarah Eisenklam Tracy Galloway Taniya Goshert Patricia Goworek Robert & Shawn Grabinski **Richard Horvitz & Erica** Hartman-Horvitz John Heropoulos & **Richard Crook** Allan & Jacqueline Hochschild **Richard & Marion Hodges** Reid Horovitz & Marlene Hollander **Ronald Jurgens** Ralph & Louise Kadden Howard Kichler David & Addie Kirchner Daniel & Stella Lentz Seth Marnin & Rachel Tiven **Clayton Mellina** Clyde & Marcia Miller Anthony Mixon Charles & Anita Newberg Adrienne Nguyen **David & Heather Niles Derek Raymond** Susan Reed Suzanne Riccardi Brian & Melanie Rickmann Kenneth Rudd Susan Salpeter **Kenneth Shigley** Solange Skyer **Diane Slater Randall Stanicky** Stuart Suna Paul & Claudia Timko Carolyn Meyer-Tolliver Hank Zureick

TOP TEN ADVANCEMENTS IN NF RESEARCH 2022

Inaugural NF Summit is held as the largest ever educational gathering for all patients, caregivers, volunteers, and advocates in the NF community.

NF2-INTUITT clinical trial expands with a second drug, neratinib, following the progress of its first drug, brigatinib.

CTF funds major MPNST study on innovative biomarker blood test for earlier diagnosis of cancer predisposition in NF1 patients.

DRIVING

RESEARCH

NF1 and NF2 gene therapy / editing projects advance quickly to non-human primates.

CTF Europe launches INFER: Masterclasses in NF and mentoring programs for all medical professionals by the world's leading NF experts.

The NF Registry grows and diversifies through availability in 5 languages: English, Spanish, French, Italian, and Portuguese.

> CTF sponsors two adult care clinics in Los Angeles, CA, and Little Rock, AR, to improve adult access to knowledgeable medical expertise.

PDVANCING CARE

NF2 and

schwannomatosis diagnostic criteria updated, with all NF manifestations now up-todate for more accurate diagnosis and improved care for patients. Partnership with FUSF explores non-invasive ultrasound treatments for NF2 patients to reduce the need for surgery, chemo, or radiation.

At the Children's Tumor Foundation, we're dedicated to bettering the lives of millions of people living with NF: all forms of neurofibromatosis and schwannomatosis. We want to end NF as fast as we can by connecting the unconnected, leading the way with a strategy that applies innovative and inventive approaches to scientific <u>advancement and improved patient care</u>. This pioneering approach attracts the brightest minds in research and industry to NF, revamps systems to accelerate the pathway from discovery to treatment, and includes the voice of the patient every step of the way.

Read about the important things that happened in NF research in 2022, which are laying the groundwork for even greater scientific advancements in the near future. Stay informed with NF research updates throughout the year at **ctf.org/news**.

Nutraceutical clinical study on curcumin and high phenolic extra virgin olive oil focuses on a combo of nutritional supplements for cutaneous and plexiform

neurofibromas

Board of Directors

Gabriel Groisman, Chair Liz Rodbell, Vice Chair Randall Stanicky, Treasurer RB Harrison, Secretary Richard Horvitz, Chair Emeritus Tracy Galloway, Chair Emeritus

Rob Brainin Dan Gilbert Sally Gottesman Frank Haughton Carol Kalagher Simone Manso Roger-Ketcha Ngassam Mark Oppenheimer Emily Parker Montse Montaner Picart Kenneth Rudd Richard Soll Stuart Suna George Thuronyi

Advisory Board Chairs

D. Wade Clapp, MD Chair, Medical Advisory Committee Scott Plotkin, MD, PhD Chair, Clinical Care Advisory Board Lu Le, MD, PhD Chair, Research Advisory Board

Lists are as of June 2023

Medical Advisory Committee

D. Wade Clapp, MD, Chair Jaishri Blakeley, MD **Michael Fisher, MD** Nader Fotouhi, PhD Aerang Kim, MD, PhD YooRi Kim, MS Bruce Korf, MD, PhD Lu Le, MD, PhD Eric Legius, MD, PhD Andrea McClatchey, PhD David Miller, MD, PhD Helen Morisson, PhD Scott Plotkin, MD, PhD Edu Serra, PhD Georg Terstappen, PhD Dave Viskochil, MD, PhD **Brigitte Widemann, MD**

Honorary Directors

Daniel Altman John Golfinos Linda Halliday Martin Steve McKenzie Carolyn Setlow

Ed Stern Pro Bono Counsel

Allan Rubenstein, MD Director of Medical Affairs Emeritus



Annette Bakker, PhD, President Elizabeth Oliver, Junior Chief of Staff Mary Thompson, Administrative Assistant

Research and Medical Programs

Brigid Garelik, MD, MPH, Chief Medical Officer Vidya Browder, PhD, Director of Research Angela Dumadag, Director of Conference & Meeting Logistics Emily Greaves, Coordinator, Patient Engagement Kate Kelts, Senior Manager, Patient Education & Engagement Elana Loftspring, Coordinator, Patient Engagement Irene Morganstern, PhD, Director, Preclinical Initiatives Marco Nievo, PhD, Chief Scientific Officer, CTF Europe Patrice Pancza, Vice President, External Relations Heather Radtke, Director, Clinical Programs

Development

Michele Przypyszny, Chief Advancement Officer Jamie Balhon, Director, Development, Cupids Amy Boulas, VP Development, P2P & Field-Based Events Cassidy Brewer, National Development Manager, Cupids Holly Cheatham, Manager, Development, Cupids Emily Crabtree, Individual Giving Officer Aidan Fraser, Development Assistant Barbara Gallagher, VP Development, Corporations & Foundations Lauren Johnston, Manager, Shine a Light NF Walk Krysta Mochi, Manager, Shine a Light NF Walk Julie Nassisi, Senior Manager, Special Events Kim Robinson, Individual Giving Officer Connie Sorman, Individual Giving Officer Rebecca Taylor, Director, Shine A Light NF Walk Lydia Vanderloo, Senior Manager, NF Endurance

Finance and Operations

Sarah Bourne, Senior VP, Finance and Operations Rachel Anderson, Senior Director, Donor Database Operations Jennifer Ching, Director, Human Resources Brianna Daquino, Accountant William Johnson, Salesforce Administrator Dan McAvoy, Operations Assistant Carey Milligan, Director of Finance Mary Phelan, UX Product Coordinator Brandon Weaver-Bey, Senior Coordinator, Gift Processing

Marketing and Communications

Simon Vukelj, Chief Marketing Officer Rebecca Harris, Director, Public Relations Alissa Marks, Senior Director, Marketing Susanne Preinfalk, Director, Design Ryan Sells, Coordinator, Communications Vanessa Younger, Senior Director, Communications Maribel Zambrana, Manager, Digital Marketing Marina Zouaghi, Data Analyst





FIGHTER. A FIGHTER

697 Third Avenue, Suite 418 | New York, NY 10017 800-323-7938 | 212-344-6633 | info@ctf.org **ctf.org**

